ID   P53_HUMAN               Reviewed;         393 AA.
AC   P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809;
AC   Q16810; Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4;
AC   Q3LRW5; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2;
AC   Q9NZD0; Q9UBI2; Q9UQ61;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 4.
DT   31-MAY-2011, entry version 186.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Antigen NY-CO-13;
DE   AltName: Full=Phosphoprotein p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=85230577; PubMed=4006916;
RA   Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
RT   "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
RT   cells.";
RL   EMBO J. 4:1251-1255(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   GLY-76.
RX   MEDLINE=87064416; PubMed=2946935;
RA   Lamb P., Crawford L.;
RT   "Characterization of the human p53 gene.";
RL   Mol. Cell. Biol. 6:1379-1385(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=85267676; PubMed=3894933;
RA   Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
RT   "Molecular cloning and in vitro expression of a cDNA clone for human
RT   cellular tumor antigen p53.";
RL   Mol. Cell. Biol. 5:1601-1610(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=87089826; PubMed=3025664;
RA   Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N.,
RA   Rotter V.;
RT   "Molecular basis for heterogeneity of the human p53 protein.";
RL   Mol. Cell. Biol. 6:4650-4656(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=89108008; PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
RA   Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P.,
RA   Georgiev G.P.;
RT   "A variation in the structure of the protein-coding region of the
RT   human p53 gene.";
RL   Gene 70:245-252(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS.
RX   MEDLINE=92007731; PubMed=1915267;
RA   Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   MEDLINE=93303270; PubMed=8316628;
RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA   Mirzayans R.;
RT   "Isolation of two cell lines from a human malignant glioma specimen
RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
RL   Radiat. Res. 134:349-354(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX.
RX   MEDLINE=21264809; PubMed=11058590; DOI=10.1074/jbc.M007140200;
RA   Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
RA   Zevotek N.;
RT   "Hyaluronidase induction of a WW domain-containing oxidoreductase that
RT   enhances tumor necrosis factor cytotoxicity.";
RL   J. Biol. Chem. 276:3361-3370(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE
RP   SPLICING, INDUCTION, AND VARIANT ARG-72.
RC   TISSUE=Colon;
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chumakov P.M., Almazov V.P., Jenkins J.R.;
RL   Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rozemuller E.H., Tilanus M.G.J.;
RT   "P53 genomic sequence. Corrections and polymorphism.";
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND
RP   ALA-366.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=11023613;
RA   Anderson C.W., Allalunis-Turner M.J.;
RT   "Human TP53 from the malignant glioma-derived cell lines M059J and
RT   M059K has a cancer-associated mutation in exon 8.";
RL   Radiat. Res. 154:473-476(2000).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND
RP   SER-309.
RA   Azuma K., Shichijo S., Itoh K.;
RT   "Identification of a tumor-rejection antigen recognized by HLA-B46
RT   restricted CTL.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-72.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-278.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139
RP   AND PRO-155.
RC   TISSUE=Lung carcinoma;
RX   PubMed=14660794; DOI=10.1073/pnas.2536558100;
RA   Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
RA   Varga J.L.;
RT   "Inhibition of mutant p53 expression and growth of DMS-153 small cell
RT   lung carcinoma by antagonists of growth hormone-releasing hormone and
RT   bombesin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393.
RX   MEDLINE=85126934; PubMed=6396087;
RA   Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L.,
RA   Benchimol S.;
RT   "Isolation and characterization of a human p53 cDNA clone: expression
RT   of the human p53 gene.";
RL   EMBO J. 3:3257-3262(1984).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185.
RA   Pan X.L., Zhang A.H.;
RT   "Study on the effect of tumor suppressor gene p53 in arsenism
RT   patients.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282.
RC   TISSUE=Blood;
RA   Nimri L.F., Owais W., Momani E.;
RT   "Detection of P53 gene mutations and serum p53 antibodies associated
RT   with cigarette smoking.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262.
RC   TISSUE=Ovarian adenocarcinoma;
RA   Filippini G., Soldati G.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RC   TISSUE=Glial cell, and Glial tumor;
RA   Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N.,
RA   Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
RT   "Mutation detection utilizing a novel PCR approach for amplification
RT   of the p53 gene from microdissected tissue: application to archival
RT   tumor samples.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RA   Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
RA   Lipsky P.E.;
RT   "Bcl6 and P53 gene mutations in tonsillar B cells.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [26]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366.
RA   Pinto E.M., Mendonca B.B., Latronico A.C.;
RT   "Allelic variant in intron 9 of TP53 gene.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [27]
RP   NUCLEAR LOCALIZATION SIGNAL.
RX   MEDLINE=90191730; PubMed=2156209;
RA   Addison C., Jenkins J.R., Sturzbecher H.-W.;
RT   "The p53 nuclear localisation signal is structurally linked to a
RT   p34cdc2 kinase motif.";
RL   Oncogene 5:423-426(1990).
RN   [28]
RP   PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
RX   MEDLINE=90280456; PubMed=2141171; DOI=10.1073/pnas.87.12.4766;
RA   Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
RT   "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
RN   [29]
RP   PHOSPHORYLATION.
RX   MEDLINE=91141509; PubMed=1705009;
RA   Samad A., Carroll R.B.;
RT   "The tumor suppressor p53 is bound to RNA by a stable covalent
RT   linkage.";
RL   Mol. Cell. Biol. 11:1598-1606(1991).
RN   [30]
RP   DEPHOSPHORYLATION BY PP2A.
RX   MEDLINE=91172186; PubMed=1848668;
RA   Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
RT   "Dephosphorylation of simian virus 40 large-T antigen and p53 protein
RT   by protein phosphatase 2A: inhibition by small-t antigen.";
RL   Mol. Cell. Biol. 11:1996-2003(1991).
RN   [31]
RP   ALTERNATIVE SPLICING.
RX   MEDLINE=96197761; PubMed=8632903;
RA   Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
RA   Gilbert D., Iggo R., Frebourg T.;
RT   "The human tumour suppressor gene p53 is alternatively spliced in
RT   normal cells.";
RL   Oncogene 12:813-818(1996).
RN   [32]
RP   GLYCOSYLATION.
RX   MEDLINE=96197773; PubMed=8632915;
RA   Shaw P., Freeman J., Bovey R., Iggo R.;
RT   "Regulation of specific DNA binding by p53: evidence for a role for O-
RT   glycosylation and charged residues at the carboxy-terminus.";
RL   Oncogene 12:921-930(1996).
RN   [33]
RP   SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386.
RA   Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E.,
RA   Scheffner M., Del Sal G.;
RT   "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-
RT   1.";
RL   EMBO J. 18:6462-6471(1999).
RN   [34]
RP   PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE,
RP   CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20
RP   AND 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND
RP   MDM2.
RX   PubMed=10570149;
RA   Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.;
RT   "Phosphorylation of Ser-20 mediates stabilization of human p53 in
RT   response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999).
RN   [35]
RP   UBIQUITINATION.
RX   MEDLINE=20187618; PubMed=10722742; DOI=10.1074/jbc.275.12.8945;
RA   Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.;
RT   "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself
RT   and p53.";
RL   J. Biol. Chem. 275:8945-8951(2000).
RN   [36]
RP   ACETYLATION AT LYS-373 AND LYS-382.
RX   MEDLINE=20123976; PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
RA   Abraham J., Kelly J., Thibault P., Benchimol S.;
RT   "Post-translational modification of p53 protein in response to
RT   ionizing radiation analyzed by mass spectrometry.";
RL   J. Mol. Biol. 295:853-864(2000).
RN   [37]
RP   FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION.
RX   PubMed=11025664; DOI=10.1038/35036365;
RA   Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.;
RT   "The function of PML in p53-dependent apoptosis.";
RL   Nat. Cell Biol. 2:730-736(2000).
RN   [38]
RP   INTERACTION WITH E4F1.
RX   PubMed=10644996; DOI=10.1038/sj.onc.1203250;
RA   Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J.,
RA   Schneider C., Del Sal G.;
RT   "p53 is involved in the p120E4F-mediated growth arrest.";
RL   Oncogene 19:188-199(2000).
RN   [39]
RP   PHOSPHORYLATION AT THR-18.
RX   MEDLINE=20406546; PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA   Lopez-Borges S., Lazo P.A.;
RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
RT   18 within the mdm-2 binding site of the p53 tumour suppressor
RT   protein.";
RL   Oncogene 19:3656-3664(2000).
RN   [40]
RP   REVIEW ON ZINC-BINDING PROPERTIES.
RX   MEDLINE=21438235; PubMed=11554448; DOI=10.1089/15230860152542961;
RA   Hainaut P., Mann K.;
RT   "Zinc binding and redox control of p53 structure and function.";
RL   Antioxid. Redox Signal. 3:611-623(2001).
RN   [41]
RP   DEACETYLATION AT LYS-382 BY SIRT1.
RX   MEDLINE=21526627; PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A.,
RA   Pandita T.K., Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [42]
RP   MINIMAL REPRESSION DOMAIN.
RX   MEDLINE=21125692; PubMed=11007800; DOI=10.1074/jbc.M008231200;
RA   Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
RT   "p53 amino acids 339-346 represent the minimal p53 repression
RT   domain.";
RL   J. Biol. Chem. 276:1510-1515(2001).
RN   [43]
RP   SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   PHE-385; LYS-386; THR-387 AND GLU-388.
RX   PubMed=11124955; DOI=10.1074/jbc.M009476200;
RA   Rodriguez M.S., Dargemont C., Hay R.T.;
RT   "SUMO-1 conjugation in vivo requires both a consensus modification
RT   motif and nuclear targeting.";
RL   J. Biol. Chem. 276:12654-12659(2001).
RN   [44]
RP   PHOSPHORYLATION BY PRPK.
RX   MEDLINE=21570176; PubMed=11546806; DOI=10.1074/jbc.M105669200;
RA   Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
RA   Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.;
RT   "Cloning and characterization of a p53-related protein kinase
RT   expressed in interleukin-2-activated cytotoxic T-cells, epithelial
RT   tumor cell lines, and the testes.";
RL   J. Biol. Chem. 276:44003-44011(2001).
RN   [45]
RP   PHOSPHORYLATION AT SER-392.
RX   PubMed=11239457; DOI=10.1016/S1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H.,
RA   Goodman R., Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2,
RT   hSpt16, and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [46]
RP   INTERACTION WITH USP7.
RX   PubMed=12507430; DOI=10.1016/S0092-8674(02)01199-6;
RA   Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E.,
RA   Shi Y.;
RT   "Crystal structure of a UBP-family deubiquitinating enzyme in
RT   isolation and in complex with ubiquitin aldehyde.";
RL   Cell 111:1041-1054(2002).
RN   [47]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   MEDLINE=21659718; PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT   death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [48]
RP   INTERACTION WITH HIPK2.
RX   MEDLINE=22191252; PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [49]
RP   INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF
RP   SER-46 AND LYS-382.
RX   MEDLINE=21638685; PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-
RT   interacting protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [50]
RP   INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46.
RX   MEDLINE=21638694; PubMed=11780126; DOI=10.1038/ncb714;
RA   D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y.,
RA   Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G.,
RA   Fanciulli M., Appella E., Soddu S.;
RT   "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46
RT   and mediates apoptosis.";
RL   Nat. Cell Biol. 4:11-19(2002).
RN   [51]
RP   INTERACTION WITH ING4.
RX   MEDLINE=22635239; PubMed=12750254;
RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
RA   Harris C.C.;
RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL   Cancer Res. 63:2373-2378(2003).
RN   [52]
RP   ACETYLATION AT LYS-305.
RX   MEDLINE=22726738; PubMed=12724314; DOI=10.1074/jbc.M212574200;
RA   Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
RT   "Identification and characterization of a novel p300-mediated p53
RT   acetylation site, lysine 305.";
RL   J. Biol. Chem. 278:25568-25576(2003).
RN   [53]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML,
RP   UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20.
RX   PubMed=12810724; DOI=10.1074/jbc.M301264200;
RA   Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P.,
RA   Haupt Y.;
RT   "The promyelocytic leukemia protein protects p53 from Mdm2-mediated
RT   inhibition and degradation.";
RL   J. Biol. Chem. 278:33134-33141(2003).
RN   [54]
RP   INTERACTION WITH P53DINP1.
RX   MEDLINE=22863074; PubMed=12851404; DOI=10.1074/jbc.M301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
RA   Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [55]
RP   NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
RX   MEDLINE=22825602; PubMed=12944468;
RX   DOI=10.1128/MCB.23.18.6396-6405.2003;
RA   O'Keefe K., Li H., Zhang Y.;
RT   "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
RT   cytoplasmic degradation but not ubiquitination.";
RL   Mol. Cell. Biol. 23:6396-6405(2003).
RN   [56]
RP   INTERACTION WITH HIPK1.
RX   MEDLINE=22608637; PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA   Mak T.W., Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the
RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [57]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=15109303; DOI=10.1042/BJ20040337;
RA   Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R.,
RA   Kaul S.C.;
RT   "Alternative reading frame protein (ARF)-independent function of CARF
RT   (collaborator of ARF) involves its interactions with p53: evidence for
RT   a novel p53-activation pathway and its negative feedback control.";
RL   Biochem. J. 380:605-610(2004).
RN   [58]
RP   INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in
RT   transcriptional activation by p53.";
RL   Cell 117:735-748(2004).
RN   [59]
RP   PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH
RP   TAF1.
RX   PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
RT   for TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [60]
RP   DEUBIQUITINATION BY USP7.
RX   PubMed=15053880; DOI=10.1016/S1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [61]
RP   ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=15340061; DOI=10.1128/MCB.24.18.7987-7997.2004;
RA   Ghosh A., Stewart D., Matlashewski G.;
RT   "Regulation of human p53 activity and cell localization by alternative
RT   splicing.";
RL   Mol. Cell. Biol. 24:7987-7997(2004).
RN   [62]
RP   METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372.
RX   PubMed=15525938; DOI=10.1038/nature03117;
RA   Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S.,
RA   McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A.,
RA   Reinberg D.;
RT   "Regulation of p53 activity through lysine methylation.";
RL   Nature 432:353-360(2004).
RN   [63]
RP   INTERACTION WITH BANP, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT
RP   SER-15.
RX   PubMed=15701641; DOI=10.1074/jbc.M413200200;
RA   Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S.,
RA   Chattopadhyay S.;
RT   "Tumor suppressor SMAR1 activates and stabilizes p53 through its
RT   arginine-serine-rich motif.";
RL   J. Biol. Chem. 280:16019-16029(2005).
RN   [64]
RP   INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
RX   PubMed=16219768; DOI=10.1074/jbc.M505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-,
RT   staurosporine-, and p53-mediated cell death, and its tyrosine 33-
RT   phosphorylated form binds and stabilizes serine 46-phosphorylated
RT   p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [65]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-392, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Colon adenocarcinoma;
RX   PubMed=16083285; DOI=10.1021/pr050048h;
RA   Kim J.-E., Tannenbaum S.R., White F.M.;
RT   "Global phosphoproteome of HT-29 human colon adenocarcinoma cells.";
RL   J. Proteome Res. 4:1339-1346(2005).
RN   [66]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [67]
RP   METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370.
RX   PubMed=17108971; DOI=10.1038/nature05287;
RA   Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M.,
RA   Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.;
RT   "Repression of p53 activity by Smyd2-mediated methylation.";
RL   Nature 444:629-632(2006).
RN   [68]
RP   INTERACTION WITH DAXX.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [69]
RP   MOTIF, AND METHYLATION AT LYS-372.
RX   PubMed=16415881; DOI=10.1038/nsmb1045;
RA   Couture J.-F., Collazo E., Hauk G., Trievel R.C.;
RT   "Structural basis for the methylation site specificity of SET7/9.";
RL   Nat. Struct. Mol. Biol. 13:140-146(2006).
RN   [70]
RP   UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION.
RX   PubMed=17170702; DOI=10.1038/sj.emboj.7601490;
RA   Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y.,
RA   Yamadera T., Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K.,
RA   Yoo E., Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S.,
RA   Eguchi K., Komiya S., Maruyama I., Higashi N., Sato M., Senoo H.,
RA   Ochi T., Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A.,
RA   Nishioka K., Tanaka K., Nakajima T.;
RT   "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident
RT   ubiquitin ligase 'Synoviolin'.";
RL   EMBO J. 26:113-122(2007).
RN   [71]
RP   INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-
RT   induced dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [72]
RP   INTERACTION WITH ARMC10.
RX   PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025;
RA   Zhou X., Yang G., Huang R., Chen X., Hu G.;
RT   "SVH-B interacts directly with p53 and suppresses the transcriptional
RT   activity of p53.";
RL   FEBS Lett. 581:4943-4948(2007).
RN   [73]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022;
RA   Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
RT   "Novel homeodomain-interacting protein kinase family member, HIPK4,
RT   phosphorylates human p53 at serine 9.";
RL   FEBS Lett. 581:5649-5657(2007).
RN   [74]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P.,
RA   Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [75]
RP   FUNCTION, AND INTERACTION WITH MAML1.
RX   PubMed=17317671; DOI=10.1074/jbc.M608974200;
RA   Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y.,
RA   Gurumurthy C.B., Germaniuk-Kurowska A., Reddi H.V., Solomon A.,
RA   Zeng M.S., Kung A., Ma H., Gao Q., Dimri G., Stanculescu A., Miele L.,
RA   Wu L., Griffin J.D., Wazer D.E., Band H., Band V.;
RT   "The notch regulator MAML1 interacts with p53 and functions as a
RT   coactivator.";
RL   J. Biol. Chem. 282:11969-11981(2007).
RN   [76]
RP   DEMETHYLATION BY KDM1A.
RX   PubMed=17805299; DOI=10.1038/nature06092;
RA   Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M.,
RA   Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.;
RT   "p53 is regulated by the lysine demethylase LSD1.";
RL   Nature 449:105-108(2007).
RN   [77]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17287340; DOI=10.1073/pnas.0611217104;
RA   Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.;
RT   "Global proteomic profiling of phosphopeptides using electron transfer
RT   dissociation tandem mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007).
RN   [78]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [79]
RP   METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382.
RX   PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012;
RA   Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W.,
RA   Dutta S., Appella E., Gozani O.;
RT   "Modulation of p53 function by SET8-mediated methylation at lysine
RT   382.";
RL   Mol. Cell 27:636-646(2007).
RN   [80]
RP   INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT
RP   SER-15 BY ATM, AND MUTAGENESIS OF SER-15.
RX   PubMed=17967874; DOI=10.1128/MCB.00983-07;
RA   Shouse G.P., Cai X., Liu X.;
RT   "Serine 15 phosphorylation of p53 directs its interaction with
RT   B56gamma and the tumor suppressor activity of B56gamma-specific
RT   protein phosphatase 2A.";
RL   Mol. Cell. Biol. 28:448-456(2008).
RN   [81]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-314; SER-315 AND
RP   SER-392, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [82]
RP   INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND
RP   UBIQUITINATION AT LYS-291 AND LYS-292 BY MKRN1.
RX   PubMed=19536131; DOI=10.1038/emboj.2009.164;
RA   Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C.,
RA   Lane D.P., Song J.;
RT   "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls
RT   cell cycle arrest and apoptosis.";
RL   EMBO J. 28:2100-2113(2009).
RN   [83]
RP   UBIQUITINATION BY TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.C109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [84]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-313; SER-314 AND
RP   SER-392, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [85]
RP   INTERACTION WITH FBXO42.
RX   PubMed=19509332; DOI=10.1073/pnas.0901864106;
RA   Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y.,
RA   Li R., Yao X., Yi X., Shang Y.;
RT   "JFK, a Kelch domain-containing F-box protein, links the SCF complex
RT   to p53 regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009).
RN   [86]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J.,
RA   Bergmann A., Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [87]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-292; LYS-305; LYS-381 AND
RP   LYS-382, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [88]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP10.
RX   PubMed=20096447; DOI=10.1016/j.cell.2009.12.032;
RA   Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.;
RT   "USP10 regulates p53 localization and stability by deubiquitinating
RT   p53.";
RL   Cell 140:384-396(2010).
RN   [89]
RP   METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373.
RX   PubMed=20118233; DOI=10.1074/jbc.M109.062588;
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X.,
RA   Jenuwein T., Reinberg D., Berger S.L.;
RT   "G9a and Glp methylate lysine 373 in the tumor suppressor p53.";
RL   J. Biol. Chem. 285:9636-9641(2010).
RN   [90]
RP   ERRATUM.
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X.,
RA   Jenuwein T., Reinberg D., Berger S.L.;
RL   J. Biol. Chem. 285:18122-18122(2010).
RN   [91]
RP   METHYLATION AT LYS-382, MUTAGENESIS OF LYS-382, AND INTERACTION WITH
RP   L3MBTL1.
RX   PubMed=20870725; DOI=10.1074/jbc.M110.139527;
RA   West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E.,
RA   Kutateladze T.G., Gozani O.;
RT   "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at
RT   lysine 382 to target gene repression.";
RL   J. Biol. Chem. 285:37725-37732(2010).
RN   [92]
RP   INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382.
RX   PubMed=20228809; DOI=10.1038/ncb2038;
RA   Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H.,
RA   Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.;
RT   "BRD7 is a candidate tumour suppressor gene required for p53
RT   function.";
RL   Nat. Cell Biol. 12:380-389(2010).
RN   [93]
RP   UBIQUITINATION BY RFWD3.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J.,
RA   Jung S.Y., O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53
RT   stability in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [94]
RP   INTERACTION WITH BRD7.
RX   PubMed=20660729; DOI=10.1073/pnas.1009559107;
RA   Burrows A.E., Smogorzewska A., Elledge S.J.;
RT   "Polybromo-associated BRG1-associated factor components BRD7 and
RT   BAF180 are critical regulators of p53 required for induction of
RT   replicative senescence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010).
RN   [95]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [96]
RP   STRUCTURE BY NMR OF 319-360.
RX   MEDLINE=94294808; PubMed=8023159; DOI=10.1126/science.8023159;
RA   Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
RA   Appella E., Gronenborn A.M.;
RT   "High-resolution structure of the oligomerization domain of p53 by
RT   multidimensional NMR.";
RL   Science 265:386-391(1994).
RN   [97]
RP   STRUCTURE BY NMR OF 325-355.
RX   MEDLINE=95292092; PubMed=7773777; DOI=10.1038/nsb1294-877;
RA   Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
RT   "Solution structure of the tetrameric minimum transforming domain of
RT   p53.";
RL   Nat. Struct. Biol. 1:877-890(1994).
RN   [98]
RP   STRUCTURE BY NMR OF 326-354.
RX   MEDLINE=98026899; PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
RA   McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
RA   Halazonetis T.D.;
RT   "Hydrophobic side-chain size is a determinant of the three-dimensional
RT   structure of the p53 oligomerization domain.";
RL   EMBO J. 16:6230-6236(1997).
RN   [99]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
RX   MEDLINE=94294806; PubMed=8023157; DOI=10.1126/science.8023157;
RA   Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
RT   "Crystal structure of a p53 tumor suppressor-DNA complex:
RT   understanding tumorigenic mutations.";
RL   Science 265:346-355(1994).
RN   [100]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
RX   MEDLINE=95184011; PubMed=7878469; DOI=10.1126/science.7878469;
RA   Jeffrey P.D., Gorina S., Pavletich N.P.;
RT   "Crystal structure of the tetramerization domain of the p53 tumor
RT   suppressor at 1.7 angstroms.";
RL   Science 267:1498-1502(1995).
RN   [101]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
RX   MEDLINE=97081050; PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
RA   Levine A.J., Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [102]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
RX   MEDLINE=97035414; PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA   Gorina S., Pavletich N.P.;
RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
RT   domains of 53BP2.";
RL   Science 274:1001-1005(1996).
RN   [103]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC
RP   IONS, AND SUBUNIT.
RX   PubMed=14534297; DOI=10.1074/jbc.M309732200;
RA   Joerger A.C., Allen M.D., Fersht A.R.;
RT   "Crystal structure of a superstable mutant of human p53 core domain.
RT   Insights into the mechanism of rescuing oncogenic mutations.";
RL   J. Biol. Chem. 279:1291-1296(2004).
RN   [104]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015;
RA   Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L.,
RA   Haran T.E., Shakked Z.;
RT   "Structural basis of DNA recognition by p53 tetramers.";
RL   Mol. Cell 22:741-753(2006).
RN   [105]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7,
RP   AND INTERACTION WITH USP7.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
RN   [106]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH
RP   USP7, MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION
RP   WITH USP7.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by
RT   HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [107]
RP   REVIEW.
RX   MEDLINE=94090335; PubMed=8266092; DOI=10.1126/science.8266092;
RA   Harris C.C.;
RT   "p53: at the crossroads of molecular carcinogenesis and risk
RT   assessment.";
RL   Science 262:1980-1981(1993).
RN   [108]
RP   REVIEW ON VARIANTS.
RX   MEDLINE=91289156; PubMed=1905840; DOI=10.1126/science.1905840;
RA   Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
RT   "p53 mutations in human cancers.";
RL   Science 253:49-53(1991).
RN   [109]
RP   REVIEW ON VARIANTS.
RX   MEDLINE=96271983; PubMed=8829653;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5;
RA   de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
RA   Liao D., Soussi T., Kovach J.S., Sommer S.S.;
RT   "Database of mutations in the p53 and APC tumor suppressor genes
RT   designed to facilitate molecular epidemiological analyses.";
RL   Hum. Mutat. 7:202-213(1996).
RN   [110]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=17015838; DOI=10.1073/pnas.0607286103;
RA   Joerger A.C., Ang H.C., Fersht A.R.;
RT   "Structural basis for understanding oncogenic p53 mutations and
RT   designing rescue drugs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006).
RN   [111]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282.
RX   PubMed=18453682; DOI=10.1107/S0907444908003338;
RA   Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.;
RT   "Impact of low-frequency hotspot mutation R282Q on the structure of
RT   p53 DNA-binding domain as revealed by crystallography at 1.54
RT   angstroms resolution.";
RL   Acta Crystallogr. D 64:471-477(2008).
RN   [112]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN
RP   COMPLEX WITH ZINC IONS AND PHIKAN083.
RX   PubMed=18650397; DOI=10.1073/pnas.0805326105;
RA   Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J.,
RA   Veprintsev D.B., Fersht A.R.;
RT   "Targeted rescue of a destabilized mutant of p53 by an in silico
RT   screened drug.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008).
RN   [113]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN
RP   COMPLEX WITH DNA.
RX   PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063;
RA   Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N.,
RA   Shimon L.J., Frolow F., Liran A., Rotter V., Shakked Z.;
RT   "Structural basis of restoring sequence-specific DNA binding and
RT   transactivation to mutant p53 by suppressor mutations.";
RL   J. Mol. Biol. 385:249-265(2009).
RN   [114]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=19515728; DOI=10.1093/protein/gzp018;
RA   Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.;
RT   "Stabilising the DNA-binding domain of p53 by rational design of its
RT   hydrophobic core.";
RL   Protein Eng. Des. Sel. 22:421-430(2009).
RN   [115]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN
RP   COMPLEX WITH ZINC IONS.
RX   PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011;
RA   Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J.,
RA   Fersht A.R.;
RT   "Toward the rational design of p53-stabilizing drugs: probing the
RT   surface of the oncogenic Y220C mutant.";
RL   Chem. Biol. 17:46-56(2010).
RN   [116]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=20364130; DOI=10.1038/nsmb.1800;
RA   Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B.,
RA   Shakked Z.;
RT   "Diversity in DNA recognition by p53 revealed by crystal structures
RT   with Hoogsteen base pairs.";
RL   Nat. Struct. Mol. Biol. 17:423-429(2010).
RN   [117]
RP   VARIANT ARG-72.
RX   MEDLINE=91153807; PubMed=1999338; DOI=10.1007/BF00201836;
RA   Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
RT   "Characterization of a frequent polymorphism in the coding sequence of
RT   the Tp53 gene in colonic cancer patients and a control population.";
RL   Hum. Genet. 86:369-370(1991).
RN   [118]
RP   VARIANT LFS THR-133.
RX   MEDLINE=92034774; PubMed=1933902;
RA   Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
RT   "A germ line mutation in exon 5 of the p53 gene in an extended cancer
RT   family.";
RL   Cancer Res. 51:6385-6387(1991).
RN   [119]
RP   VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
RX   MEDLINE=91057657; PubMed=1978757; DOI=10.1126/science.1978757;
RA   Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E.,
RA   Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A.,
RA   Friend S.H.;
RT   "Germ line p53 mutations in a familial syndrome of breast cancer,
RT   sarcomas, and other neoplasms.";
RL   Science 250:1233-1238(1990).
RN   [120]
RP   VARIANT LFS ASP-245.
RX   MEDLINE=91080929; PubMed=2259385; DOI=10.1038/348747a0;
RA   Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
RT   "Germ-line transmission of a mutated p53 gene in a cancer-prone family
RT   with Li-Fraumeni syndrome.";
RL   Nature 348:747-749(1990).
RN   [121]
RP   VARIANT LFS LEU-272.
RX   MEDLINE=92147883; PubMed=1737852; DOI=10.1172/JCI115630;
RA   Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I.,
RA   Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J.,
RA   Knutsen T., Minna J.D.;
RT   "Hereditary and acquired p53 gene mutations in childhood acute
RT   lymphoblastic leukemia.";
RL   J. Clin. Invest. 89:640-647(1992).
RN   [122]
RP   VARIANTS LFS HIS-273 AND VAL-325.
RX   MEDLINE=92228023; PubMed=1565144;
RA   Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H.,
RA   Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J.,
RA   Strong L.C.;
RT   "Germline mutations of the p53 tumor-suppressor gene in children and
RT   young adults with second malignant neoplasms.";
RL   N. Engl. J. Med. 326:1309-1315(1992).
RN   [123]
RP   VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285.
RX   MEDLINE=90295284; PubMed=1694291;
RA   Bartek J., Iggo R., Gannon J., Lane D.P.;
RT   "Genetic and immunochemical analysis of mutant p53 in human breast
RT   cancer cell lines.";
RL   Oncogene 5:893-899(1990).
RN   [124]
RP   VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273.
RX   MEDLINE=91017544; PubMed=1699228; DOI=10.1073/pnas.87.19.7555;
RA   Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
RA   Gannon J.V., Lane D.P.;
RT   "p53 mutations in colorectal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
RN   [125]
RP   VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND
RP   SER-278.
RX   MEDLINE=91088630; PubMed=2263646; DOI=10.1073/pnas.87.24.9958;
RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
RN   [126]
RP   VARIANTS SPORADIC CANCERS.
RX   MEDLINE=91282784; PubMed=1647768; DOI=10.1016/0006-291X(91)90623-F;
RA   Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
RA   Wakui A., Yamazaki T.;
RT   "Mutations of the P53 gene, including an intronic point mutation, in
RT   colorectal tumors.";
RL   Biochem. Biophys. Res. Commun. 177:901-906(1991).
RN   [127]
RP   VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND
RP   HIS-273.
RX   MEDLINE=91330175; PubMed=1868473;
RA   Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B.,
RA   Roth J.A.;
RT   "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
RL   Cancer Res. 51:4495-4499(1991).
RN   [128]
RP   VARIANTS SPORADIC CANCERS IN CHINA.
RX   MEDLINE=91187113; PubMed=1849234; DOI=10.1038/350427a0;
RA   Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
RT   "Mutational hotspot in the p53 gene in human hepatocellular
RT   carcinomas.";
RL   Nature 350:427-428(1991).
RN   [129]
RP   VARIANTS SPORADIC CANCERS IN SOUTH AFRICA.
RX   MEDLINE=91187114; PubMed=1672732; DOI=10.1038/350429a0;
RA   Bressac B., Kew M., Wands J., Ozturk M.;
RT   "Selective G to T mutations of p53 gene in hepatocellular carcinoma
RT   from southern Africa.";
RL   Nature 350:429-431(1991).
RN   [130]
RP   VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND
RP   HIS-273.
RX   MEDLINE=93007999; PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RN   [131]
RP   VARIANTS SPORADIC CANCERS.
RX   MEDLINE=93010989; PubMed=1327751;
RA   Crook T., Vousden K.H.;
RT   "Properties of p53 mutations detected in primary and secondary
RT   cervical cancers suggest mechanisms of metastasis and involvement of
RT   environmental carcinogens.";
RL   EMBO J. 11:3935-3940(1992).
RN   [132]
RP   VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285.
RX   MEDLINE=93093790; PubMed=1459726; DOI=10.1002/ijc.2910520606;
RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA   Yamamoto H., Tsuchida N.;
RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral
RT   squamous-cell carcinoma.";
RL   Int. J. Cancer 52:867-872(1992).
RN   [133]
RP   VARIANT PRO-HIS-PRO-178 INS.
RX   MEDLINE=93265016; PubMed=1303181; DOI=10.1093/hmg/1.3.207;
RA   Bhatia K., Guiterrez M.I., Magrath I.T.;
RT   "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
RL   Hum. Mol. Genet. 1:207-208(1992).
RN   [134]
RP   VARIANTS SPORADIC CANCERS.
RX   MEDLINE=93064692; PubMed=1437144;
RA   Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
RA   Appella E., May P.;
RT   "p53 mutations in Raji cells: characterization and localization
RT   relative to other Burkitt's lymphomas.";
RL   Oncogene 7:2161-2167(1992).
RN   [135]
RP   VARIANT SPORADIC CANCER THR-280.
RX   MEDLINE=92335329; PubMed=1631151; DOI=10.1073/pnas.89.14.6516;
RA   Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y.,
RA   Chen I.-H., Cao Y., Yao K.-T., Colburn N.H.;
RT   "An infrequent point mutation of the p53 gene in human nasopharyngeal
RT   carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
RN   [136]
RP   VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220;
RP   GLN-248; LEU-248 AND HIS-273.
RX   MEDLINE=93235942; PubMed=7682763;
RA   Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
RT   "p53 alterations in human squamous cell carcinomas and carcinoma cell
RT   lines.";
RL   Am. J. Pathol. 142:1131-1139(1993).
RN   [137]
RP   VARIANTS SPORADIC CANCERS.
RX   MEDLINE=94006220; PubMed=8402617;
RA   Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
RA   Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
RT   "The incidence of p53 mutations increases with progression of head and
RT   neck cancer.";
RL   Cancer Res. 53:4477-4480(1993).
RN   [138]
RP   VARIANTS SPORADIC CANCERS.
RX   MEDLINE=93330562; PubMed=8336944;
RA   Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
RT   "Efficient screening of p53 mutations by denaturing gradient gel
RT   electrophoresis in colorectal tumors.";
RL   Oncogene 8:2213-2220(1993).
RN   [139]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8118819;
RA   Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A.,
RA   Kelsey A.M., Harris M., Jones P.H., Binchy A., Crowther D.,
RA   Craft A.W., Eden O.B., Evans D.G.R., Thompson E., Mann J.R.,
RA   Martin J., Mitchell E.L.D., Santibanez-Koref M.F.;
RT   "Prevalence and diversity of constitutional mutations in the p53 gene
RT   among 21 Li-Fraumeni families.";
RL   Cancer Res. 54:1298-1304(1994).
RN   [140]
RP   CHARACTERIZATION OF VARIANT ALA-143.
RX   MEDLINE=94283378; PubMed=8013454;
RA   Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
RT   "A temperature-sensitive mutant of human p53.";
RL   EMBO J. 13:2535-2544(1994).
RN   [141]
RP   VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
RX   MEDLINE=95193787; PubMed=7887414;
RA   Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
RA   Fraumeni J.F. Jr., Li F.P., Friend S.H.;
RT   "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
RL   Am. J. Hum. Genet. 56:608-615(1995).
RN   [142]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8718514;
RA   Eeles R.A.;
RT   "Germline mutations in the TP53 gene.";
RL   Cancer Surv. 25:101-124(1995).
RN   [143]
RP   VARIANT LFS HIS-175.
RX   MEDLINE=96423319; PubMed=8825920;
RA   Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
RA   Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M.,
RA   Evans D.G.R.;
RT   "An extended Li-Fraumeni kindred with gastric carcinoma and a codon
RT   175 mutation in TP53.";
RL   J. Med. Genet. 32:942-945(1995).
RN   [144]
RP   VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND
RP   GLN-286.
RX   MEDLINE=96233927; PubMed=8829627;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0;
RA   Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B.,
RA   Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
RT   "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
RL   Hum. Mutat. 7:109-113(1996).
RN   [145]
RP   VARIANTS SPORADIC CANCERS.
RX   MEDLINE=97255965; PubMed=9101296;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7;
RA   Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
RA   Zeuthen J.;
RT   "Single-step DGGE-based mutation scanning of the p53 gene: application
RT   to genetic diagnosis of colorectal cancer.";
RL   Hum. Mutat. 9:348-355(1997).
RN   [146]
RP   VARIANT SPORADIC CANCER ILE-157.
RX   MEDLINE=98080146; PubMed=9419979; DOI=10.1038/sj.onc.1201668;
RA   Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
RA   Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
RA   Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
RT   "Drastic genetic instability of tumors and normal tissues in Turcot
RT   syndrome.";
RL   Oncogene 15:2877-2881(1997).
RN   [147]
RP   VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273
RP   AND SER-278.
RX   MEDLINE=98111377; PubMed=9450901;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G;
RA   van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
RA   Raubenheimer E.J.;
RT   "Detection of p53 gene mutations in oral squamous cell carcinomas of a
RT   black African population sample.";
RL   Hum. Mutat. 11:39-44(1998).
RN   [148]
RP   VARIANT NON-CLASSICAL LFS CYS-337.
RX   MEDLINE=98112421; PubMed=9452042;
RA   Luca J.W., Strong L.C., Hansen M.F.;
RT   "A germline missense mutation R337C in exon 10 of the human p53
RT   gene.";
RL   Hum. Mutat. Suppl. 1:S58-S61(1998).
RN   [149]
RP   VARIANT LFS ILE-292.
RX   MEDLINE=99414637; PubMed=10484981; DOI=10.1016/S0165-4608(98)00276-3;
RA   Gueran S., Tunca Y., Imirzalioglu N.;
RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in
RT   a Li-Fraumeni syndrome family.";
RL   Cancer Genet. Cytogenet. 113:145-151(1999).
RN   [150]
RP   VARIANTS.
RX   PubMed=10549356;
RA   Hainaut P., Hollstein M.;
RT   "p53 and human cancer: the first ten thousand mutations.";
RL   Adv. Cancer Res. 77:81-137(2000).
RN   [151]
RP   VARIANT ADCC HIS-337.
RX   PubMed=11481490; DOI=10.1073/pnas.161479898;
RA   Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P.,
RA   Michalkiewicz E., Lafferty A.R., DeLacerda L., Rabin M., Cadwell C.,
RA   Sampaio G., Cat I., Stratakis C.A., Sandrini R.;
RT   "An inherited p53 mutation that contributes in a tissue-specific
RT   manner to pediatric adrenal cortical carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001).
RN   [152]
RP   INVOLVEMENT IN CPLPA.
RX   MEDLINE=22079076; PubMed=12085209; DOI=10.1038/sj.bjc.6600269;
RA   Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P.,
RA   Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
RT   "Investigations on a clinically and functionally unusual and novel
RT   germline p53 mutation.";
RL   Br. J. Cancer 86:1592-1596(2002).
RN   [153]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175;
RP   ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248;
RP   SER-249; TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280
RP   AND HIS-281.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [154]
RP   VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195;
RP   MET-216; ALA-241; MET-249; SER-251; TYR-259 AND CYS-273.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A.,
RA   Presswalla S., Kaaresen R., Strausberg R.L., Gerhard D.S.,
RA   Kristensen V., Perou C.M., Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by
RT   expression profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [155]
RP   VARIANTS.
RX   PubMed=17311302; DOI=10.1002/humu.20495;
RA   Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V.,
RA   Hainaut P., Olivier M.;
RT   "Impact of mutant p53 functional properties on TP53 mutation patterns
RT   and tumor phenotype: lessons from recent developments in the IARC TP53
RT   database.";
RL   Hum. Mutat. 28:622-629(2007).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. Implicated in Notch signaling cross-over. Isoform 2
CC       enhances the transactivation activity of isoform 1 from some but
CC       not all TP53-inducible promoters. Isoform 4 suppresses
CC       transactivation activity and impairs growth suppression mediated
CC       by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
CC   -!- COFACTOR: Binds 1 zinc ion per subunit.
CC   -!- SUBUNIT: Interacts with AXIN1. Probably part of a complex
CC       consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as
CC       a homotetramer. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. In vitro, the interaction of TP53 with cancer-
CC       associated/HPV (E6) viral proteins leads to ubiquitination and
CC       degradation of TP53 giving a possible model for cell growth
CC       regulation. This complex formation requires an additional factor,
CC       E6-AP, which stably associates with TP53 in the presence of E6.
CC       Interacts (via C-terminus) with TAF1; when TAF1 is part of the
CC       TFIID complex. Interacts with ING4; this interaction may be
CC       indirect. Found in a complex with CABLES1 and TP73. Interacts with
CC       HIPK1, HIPK2, and P53DINP1. Interacts with WWOX. May interact with
CC       HCV core protein. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and
CC       prevent transactivation activity (By similarity). Interacts with
CC       ARMC10, BANP, CDKN2AIP and E4F1. Interacts with YWHAZ; the
CC       interaction enhances TP53 transcriptional activity.
CC       Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction.
CC       Interacts (via DNA-binding domain) with MAML1 (via N-terminus).
CC       Interacts with MKRN1. Interacts with PML (via C-terminus).
CC       Interacts with MDM2; leading to ubiquitination and proteasomal
CC       degradation of TP53. Directly interacts with FBXO42; leading to
CC       ubiquination and degradation of TP53. Interacts (phosphorylated at
CC       Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme;
CC       regulates stress-induced TP53-dependent inhibition of cell
CC       proliferation. Interacts with PPP2R2A. Interacts with DAXX, BRD7
CC       and TRIM24. Interacts (when monomethylated at Lys-382) with
CC       L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4.
CC   -!- INTERACTION:
CC       P03070:- (xeno); NbExp=4; IntAct=EBI-366083, EBI-617698;
CC       Q13535:ATR; NbExp=1; IntAct=EBI-366083, EBI-968983;
CC       Q99728:BARD1; NbExp=1; IntAct=EBI-366083, EBI-473181;
CC       O70445:Bard1 (xeno); NbExp=1; IntAct=EBI-366083, EBI-1790207;
CC       Q07817-1:BCL2L1; NbExp=2; IntAct=EBI-366083, EBI-287195;
CC       P51813:BMX; NbExp=1; IntAct=EBI-366083, EBI-696657;
CC       Q9BX70:BTBD2; NbExp=1; IntAct=EBI-366083, EBI-710091;
CC       Q8TDN4:CABLES1; NbExp=1; IntAct=EBI-366083, EBI-604615;
CC       Q9ESJ1:Cables1 (xeno); NbExp=1; IntAct=EBI-366083, EBI-604411;
CC       P17676:CEBPB; NbExp=3; IntAct=EBI-366083, EBI-969696;
CC       Q92793:CREBBP; NbExp=3; IntAct=EBI-366083, EBI-81215;
CC       P45481:Crebbp (xeno); NbExp=2; IntAct=EBI-366083, EBI-296306;
CC       P55060:CSE1L; NbExp=4; IntAct=EBI-366083, EBI-286709;
CC       Q14999:CUL7; NbExp=1; IntAct=EBI-366083, EBI-308606;
CC       Q8IWT3:CUL9; NbExp=1; IntAct=EBI-366083, EBI-311123;
CC       Q9UER7:DAXX; NbExp=3; IntAct=EBI-366083, EBI-77321;
CC       Q9BV47:DUSP26; NbExp=6; IntAct=EBI-366083, EBI-2924519;
CC       Q09472:EP300; NbExp=3; IntAct=EBI-366083, EBI-447295;
CC       Q86XK2:FBXO11; NbExp=3; IntAct=EBI-366083, EBI-1047804;
CC       Q9BVP2:GNL3; NbExp=1; IntAct=EBI-366083, EBI-641642;
CC       Q13547:HDAC1; NbExp=1; IntAct=EBI-366083, EBI-301834;
CC       Q86Z02:HIPK1; NbExp=1; IntAct=EBI-366083, EBI-692891;
CC       P09429:HMGB1; NbExp=1; IntAct=EBI-366083, EBI-389432;
CC       Q9BUJ2:HNRNPUL1; NbExp=6; IntAct=EBI-366083, EBI-1018153;
CC       P42858:HTT; NbExp=2; IntAct=EBI-366083, EBI-466029;
CC       Q7Z6Z7:HUWE1; NbExp=2; IntAct=EBI-366083, EBI-625934;
CC       Q8N9B5:JMY; NbExp=1; IntAct=EBI-366083, EBI-866435;
CC       Q92993:KAT5; NbExp=1; IntAct=EBI-366083, EBI-399080;
CC       Q15759:MAPK11; NbExp=1; IntAct=EBI-366083, EBI-298304;
CC       Q8IW41:MAPKAPK5; NbExp=1; IntAct=EBI-366083, EBI-1201460;
CC       Q00987:MDM2; NbExp=9; IntAct=EBI-366083, EBI-389668;
CC       P56273:mdm2 (xeno); NbExp=1; IntAct=EBI-366083, EBI-541233;
CC       O15151:MDM4; NbExp=2; IntAct=EBI-366083, EBI-398437;
CC       P23511:NFYA; NbExp=2; IntAct=EBI-366083, EBI-389739;
CC       P06748:NPM1; NbExp=3; IntAct=EBI-366083, EBI-78579;
CC       P06748-1:NPM1; NbExp=1; IntAct=EBI-366083, EBI-354150;
CC       P09874:PARP1; NbExp=1; IntAct=EBI-366083, EBI-355676;
CC       Q96KB5:PBK; NbExp=6; IntAct=EBI-366083, EBI-536853;
CC       O75925:PIAS1; NbExp=1; IntAct=EBI-366083, EBI-629434;
CC       Q8N2W9:PIAS4; NbExp=1; IntAct=EBI-366083, EBI-473160;
CC       P29590:PML; NbExp=1; IntAct=EBI-366083, EBI-295890;
CC       P36873-1:PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289;
CC       Q05397:PTK2; NbExp=6; IntAct=EBI-366083, EBI-702142;
CC       Q06609:RAD51; NbExp=1; IntAct=EBI-366083, EBI-297202;
CC       P27694:RPA1; NbExp=1; IntAct=EBI-366083, EBI-621389;
CC       P62991:Rps27a (xeno); NbExp=1; IntAct=EBI-366083, EBI-413074;
CC       Q8WTS6:SETD7; NbExp=3; IntAct=EBI-366083, EBI-1268586;
CC       Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
CC       P20226:TBP; NbExp=1; IntAct=EBI-366083, EBI-355371;
CC       Q13625:TP53BP2; NbExp=1; IntAct=EBI-366083, EBI-77642;
CC       Q9H3D4:TP63; NbExp=1; IntAct=EBI-366083, EBI-2337775;
CC       O88898:Tp63 (xeno); NbExp=1; IntAct=EBI-366083, EBI-2338025;
CC       P0CG47:UBB; NbExp=1; IntAct=EBI-366083, EBI-413034;
CC       Q05086:UBE3A; NbExp=1; IntAct=EBI-366083, EBI-954357;
CC       Q93009:USP7; NbExp=5; IntAct=EBI-366083, EBI-302474;
CC       P11473:VDR; NbExp=2; IntAct=EBI-366083, EBI-286357;
CC       Q14191:WRN; NbExp=2; IntAct=EBI-366083, EBI-368417;
CC       P12956:XRCC6; NbExp=1; IntAct=EBI-366083, EBI-353208;
CC       Q96PM9:ZNF385A; NbExp=1; IntAct=EBI-366083, EBI-1539778;
CC       Q9PST7:znf585b (xeno); NbExp=2; IntAct=EBI-366083, EBI-1782562;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, PML body.
CC       Endoplasmic reticulum. Note=Interaction with BANP promotes nuclear
CC       localization. Recruited into PML bodies together with CHEK2.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but localizes to the cytoplasm when
CC       expressed with isoform 4.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus. Cytoplasm.
CC       Note=Localized mainly in the nucleus with minor staining in the
CC       cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm.
CC       Note=Localized in the nucleus in most cells but found in the
CC       cytoplasm in some cells.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but translocates to the cytoplasm
CC       following cell stress.
CC   -!- SUBCELLULAR LOCATION: Isoform 7: Nucleus. Cytoplasm.
CC       Note=Localized mainly in the nucleus with minor staining in the
CC       cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform 8: Nucleus. Cytoplasm.
CC       Note=Localized in both nucleus and cytoplasm in most cells. In
CC       some cells, forms foci in the nucleus that are different from
CC       nucleoli.
CC   -!- SUBCELLULAR LOCATION: Isoform 9: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=p53, p53alpha;
CC         IsoId=P04637-1; Sequence=Displayed;
CC       Name=2; Synonyms=I9RET, p53beta;
CC         IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
CC         Note=Expressed in quiescent lymphocytes. Seems to be
CC         non-functional. May be produced at very low levels due to a
CC         premature stop codon in the mRNA, leading to nonsense-mediated
CC         mRNA decay;
CC       Name=3; Synonyms=p53gamma;
CC         IsoId=P04637-3; Sequence=VSP_040560, VSP_040561;
CC         Note=Expressed in quiescent lymphocytes. Seems to be
CC         non-functional. May be produced at very low levels due to a
CC         premature stop codon in the mRNA, leading to nonsense-mediated
CC         mRNA decay;
CC       Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47;
CC         IsoId=P04637-4; Sequence=VSP_040832;
CC       Name=5; Synonyms=Del40-p53beta;
CC         IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536;
CC       Name=6; Synonyms=Del40-p53gamma;
CC         IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561;
CC       Name=7; Synonyms=Del133-p53, Del133-p53alpha;
CC         IsoId=P04637-7; Sequence=VSP_040833;
CC         Note=Produced by alternative promoter usage;
CC       Name=8; Synonyms=Del133-p53beta;
CC         IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536;
CC         Note=Produced by alternative promoter usage and alternative
CC         splicing;
CC       Name=9; Synonyms=Del133-p53gamma;
CC         IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561;
CC         Note=Produced by alternative promoter usage and alternative
CC         splicing;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide
CC       range of normal tissues but in a tissue-dependent manner. Isoform
CC       2 is expressed in most normal tissues but is not detected in
CC       brain, lung, prostate, muscle, fetal brain, spinal cord and fetal
CC       liver. Isoform 3 is expressed in most normal tissues but is not
CC       detected in lung, spleen, testis, fetal brain, spinal cord and
CC       fetal liver. Isoform 7 is expressed in most normal tissues but is
CC       not detected in prostate, uterus, skeletal muscle and breast.
CC       Isoform 8 is detected only in colon, bone marrow, testis, fetal
CC       brain and intestine. Isoform 9 is expressed in most normal tissues
CC       but is not detected in brain, heart, lung, fetal liver, salivary
CC       gland, breast or intestine.
CC   -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is
CC       not induced in tumor cells in response to stress.
CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional
CC       repression domain. The TADI and TADII motifs (residues 17 to 25
CC       and 48 to 56) correspond both to 9aaTAD motifs which are
CC       transactivation domains present in a large number of yeast and
CC       animal transcription factors.
CC   -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
CC       transcriptional activity. Deacetylation of Lys-382 by SIRT1
CC       impairs its ability to induce proapoptotic program and modulate
CC       cell senescence.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated by HIPK1 (By similarity).
CC       Phosphorylation at Ser-9 by HIPK4 increases repression activity on
CC       BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated
CC       on Ser-20 by CHEK2 in response to DNA damage, which prevents
CC       ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which
CC       promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by
CC       HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required
CC       for acetylation by CREBBP. Phosphorylated on Ser-392 following UV
CC       but not gamma irradiation. Phosphorylated upon DNA damage,
CC       probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet
CC       irradiation; which is enhanced by interaction with BANP.
CC   -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40
CC       small T antigen inhibits the dephosphorylation by the AC form of
CC       PP2A.
CC   -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied
CC       in EB-1 cell line.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to its
CC       stabilization. Ubiquitinated by TRIM24, which leads to proteasomal
CC       degradation. Ubiquitination by TOPORS induces degradation.
CC       Deubiquitination by USP7, leading to stabilization. Isoform 4 is
CC       monoubiquitinated in an MDM2-independent manner.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-370 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation.
CC   -!- PTM: Sumoylated by SUMO1.
CC   -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety
CC       of transformed cells. TP53 is frequently mutated or inactivated in
CC       about 60% of cancers. TP53 defects are found in Barrett metaplasia
CC       a condition in which the normally stratified squamous epithelium
CC       of the lower esophagus is replaced by a metaplastic columnar
CC       epithelium. The condition develops as a complication in
CC       approximately 10% of patients with chronic gastroesophageal reflux
CC       disease and predisposes to the development of esophageal
CC       adenocarcinoma.
CC   -!- DISEASE: Defects in TP53 are a cause of esophageal cancer (ESCR)
CC       [MIM:133239].
CC   -!- DISEASE: Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS)
CC       [MIM:151623]. LFS is an autosomal dominant familial cancer
CC       syndrome that in its classic form is defined by the existence of a
CC       proband affected by a sarcoma before 45 years with a first degree
CC       relative affected by any tumor before 45 years and another first
CC       degree relative with any tumor before 45 years or a sarcoma at any
CC       age. Other clinical definitions for LFS have been proposed
CC       (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like
CC       syndrome (LFL). In these families affected relatives develop a
CC       diverse set of malignancies at unusually early ages. Four types of
CC       cancers account for 80% of tumors occurring in TP53 germline
CC       mutation carriers: breast cancers, soft tissue and bone sarcomas,
CC       brain tumors (astrocytomas) and adrenocortical carcinomas. Less
CC       frequent tumors include choroid plexus carcinoma or papilloma
CC       before the age of 15, rhabdomyosarcoma before the age of 5,
CC       leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and
CC       gastric cancers.
CC   -!- DISEASE: Defects in TP53 are involved in head and neck squamous
CC       cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell
CC       carcinoma of the head and neck.
CC   -!- DISEASE: Defects in TP53 are a cause of lung cancer (LNCR)
CC       [MIM:211980].
CC   -!- DISEASE: Defects in TP53 are a cause of choroid plexus papilloma
CC       (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing
CC       benign tumor of the choroid plexus that often invades the
CC       leptomeninges. In children it is usually in a lateral ventricle
CC       but in adults it is more often in the fourth ventricle.
CC       Hydrocephalus is common, either from obstruction or from tumor
CC       secretion of cerebrospinal fluid. If it undergoes malignant
CC       transformation it is called a choroid plexus carcinoma. Primary
CC       choroid plexus tumors are rare and usually occur in early
CC       childhood.
CC   -!- DISEASE: Defects in TP53 are a cause of adrenocortical carcinoma
CC       (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal
CC       cortex. It occurs with increased frequency in patients with the
CC       Beckwith-Wiedemann syndrome and is a component tumor in Li-
CC       Fraumeni syndrome.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC   -!- WEB RESOURCE: Name=IARC TP53 mutation database; Note=Somatic and
CC       germline TP53 mutations in human cancers;
CC       URL="http://www-p53.iarc.fr/";
CC   -!- WEB RESOURCE: Name=p53 web site at the Institut Curie;
CC       URL="http://p53.free.fr/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/P53ID88.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/TP53";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tp53/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TP53";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry;
CC       URL="http://en.wikipedia.org/wiki/P53";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02469; CAA26306.1; -; mRNA.
DR   EMBL; M13121; AAA59987.1; -; Genomic_DNA.
DR   EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; K03199; AAA59989.1; -; mRNA.
DR   EMBL; M14694; AAA61211.1; -; mRNA.
DR   EMBL; M14695; AAA61212.1; -; mRNA.
DR   EMBL; M22898; AAA59988.1; -; Genomic_DNA.
DR   EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; X01405; CAA25652.1; -; mRNA.
DR   EMBL; X60011; CAA42626.1; -; mRNA.
DR   EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
DR   EMBL; X60013; CAA42628.1; -; mRNA.
DR   EMBL; X60014; CAA42629.1; -; mRNA.
DR   EMBL; X60015; CAA42630.1; -; mRNA.
DR   EMBL; X60016; CAA42631.1; -; mRNA.
DR   EMBL; X60017; CAA42632.1; -; mRNA.
DR   EMBL; X60018; CAA42633.1; -; mRNA.
DR   EMBL; X60019; CAA42634.1; -; mRNA.
DR   EMBL; X60020; CAA42635.1; -; mRNA.
DR   EMBL; AF307851; AAG28785.1; -; mRNA.
DR   EMBL; DQ186648; ABA29753.1; -; mRNA.
DR   EMBL; DQ186649; ABA29754.1; -; mRNA.
DR   EMBL; DQ186650; ABA29755.1; -; mRNA.
DR   EMBL; DQ186651; ABA29756.1; -; mRNA.
DR   EMBL; DQ186652; ABA29757.1; -; mRNA.
DR   EMBL; DQ191317; ABB80262.1; -; mRNA.
DR   EMBL; DQ286964; ABB80266.1; -; mRNA.
DR   EMBL; X54156; CAA38095.1; -; Genomic_DNA.
DR   EMBL; U94788; AAC12971.1; -; Genomic_DNA.
DR   EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
DR   EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
DR   EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
DR   EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
DR   EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
DR   EMBL; AB082923; BAC16799.1; -; mRNA.
DR   EMBL; AK312568; BAG35463.1; -; mRNA.
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90143.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90144.1; -; Genomic_DNA.
DR   EMBL; BC003596; AAH03596.1; -; mRNA.
DR   EMBL; AY429684; AAR10356.1; -; mRNA.
DR   EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
DR   EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
DR   EMBL; U63714; AAB39322.1; -; Genomic_DNA.
DR   EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
DR   EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
DR   EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
DR   EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
DR   EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
DR   EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
DR   EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
DR   EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
DR   EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
DR   EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
DR   EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
DR   EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
DR   EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
DR   EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
DR   EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
DR   EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
DR   EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
DR   EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
DR   EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
DR   EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
DR   EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
DR   EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
DR   EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
DR   EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
DR   IPI; IPI00025087; -.
DR   IPI; IPI00375319; -.
DR   IPI; IPI00796188; -.
DR   IPI; IPI00894418; -.
DR   IPI; IPI00895905; -.
DR   IPI; IPI00973801; -.
DR   IPI; IPI01008713; -.
DR   IPI; IPI01009016; -.
DR   IPI; IPI01009039; -.
DR   PIR; A25224; DNHU53.
DR   RefSeq; NP_000537.3; NM_000546.4.
DR   RefSeq; NP_001119584.1; NM_001126112.1.
DR   RefSeq; NP_001119585.1; NM_001126113.1.
DR   RefSeq; NP_001119586.1; NM_001126114.1.
DR   RefSeq; NP_001119587.1; NM_001126115.1.
DR   RefSeq; NP_001119588.1; NM_001126116.1.
DR   RefSeq; NP_001119589.1; NM_001126117.1.
DR   UniGene; Hs.654481; -.
DR   PDB; 1A1U; NMR; -; A/C=324-358.
DR   PDB; 1AIE; X-ray; 1.50 A; A=326-356.
DR   PDB; 1C26; X-ray; 1.70 A; A=325-356.
DR   PDB; 1DT7; NMR; -; X/Y=367-388.
DR   PDB; 1GZH; X-ray; 2.60 A; A/C=95-292.
DR   PDB; 1H26; X-ray; 2.24 A; E=376-386.
DR   PDB; 1HS5; NMR; -; A/B=324-357.
DR   PDB; 1JSP; NMR; -; A=367-386.
DR   PDB; 1KZY; X-ray; 2.50 A; A/B=95-289.
DR   PDB; 1MA3; X-ray; 2.00 A; B=372-389.
DR   PDB; 1OLG; NMR; -; A/B/C/D=319-360.
DR   PDB; 1OLH; NMR; -; A/B/C/D=319-360.
DR   PDB; 1PES; NMR; -; A/B/C/D=325-355.
DR   PDB; 1PET; NMR; -; A/B/C/D=325-355.
DR   PDB; 1SAE; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAF; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAH; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAJ; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAL; NMR; -; A/B/C/D=319-360.
DR   PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1UOL; X-ray; 1.90 A; A/B=94-312.
DR   PDB; 1XQH; X-ray; 1.75 A; B/F=369-377.
DR   PDB; 1YC5; X-ray; 1.40 A; B=372-389.
DR   PDB; 1YCQ; X-ray; 2.30 A; B=13-29.
DR   PDB; 1YCR; X-ray; 2.60 A; B=15-29.
DR   PDB; 1YCS; X-ray; 2.20 A; A=94-292.
DR   PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 2ADY; X-ray; 2.50 A; A/B=94-293.
DR   PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293.
DR   PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293.
DR   PDB; 2B3G; X-ray; 1.60 A; B=33-60.
DR   PDB; 2BIM; X-ray; 1.98 A; A/B=94-312.
DR   PDB; 2BIN; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIO; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIP; X-ray; 1.80 A; A=94-312.
DR   PDB; 2BIQ; X-ray; 1.80 A; A=94-312.
DR   PDB; 2F1X; X-ray; 2.30 A; A/B=359-368.
DR   PDB; 2FEJ; NMR; -; A=94-297.
DR   PDB; 2FOJ; X-ray; 1.60 A; B=363-367.
DR   PDB; 2FOO; X-ray; 2.20 A; B=358-363.
DR   PDB; 2GS0; NMR; -; B=20-73.
DR   PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292.
DR   PDB; 2H2D; X-ray; 1.70 A; B=372-389.
DR   PDB; 2H2F; X-ray; 2.20 A; B=372-389.
DR   PDB; 2H4F; X-ray; 2.00 A; D=372-389.
DR   PDB; 2H4H; X-ray; 1.99 A; B=372-389.
DR   PDB; 2H4J; X-ray; 2.10 A; D=372-389.
DR   PDB; 2H59; X-ray; 1.90 A; D/E=372-389.
DR   PDB; 2J0Z; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J10; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J11; NMR; -; A/B/C/D=332-356.
DR   PDB; 2J1W; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J1X; X-ray; 1.65 A; A/B=94-312.
DR   PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293.
DR   PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J20; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J21; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2K8F; NMR; -; B=1-39.
DR   PDB; 2L14; NMR; -; B=13-61.
DR   PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312.
DR   PDB; 2PCX; X-ray; 1.54 A; A=94-292.
DR   PDB; 2QVQ; X-ray; 2.00 A; A=94-289.
DR   PDB; 2QXA; X-ray; 1.50 A; A/B/C/D=95-289.
DR   PDB; 2QXB; X-ray; 2.50 A; A/B/C/D=95-289.
DR   PDB; 2QXC; X-ray; 1.85 A; A/B/C/D=95-289.
DR   PDB; 2VUK; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 2WGX; X-ray; 1.75 A; A/B=94-310.
DR   PDB; 2X0U; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2X0V; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2X0W; X-ray; 2.10 A; A/B=94-312.
DR   PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 3D05; X-ray; 1.70 A; A=94-293.
DR   PDB; 3D06; X-ray; 1.20 A; A=94-293.
DR   PDB; 3D07; X-ray; 2.20 A; A/B=94-293.
DR   PDB; 3D08; X-ray; 1.40 A; A=94-293.
DR   PDB; 3D09; X-ray; 1.90 A; A=94-293.
DR   PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29.
DR   PDB; 3DAC; X-ray; 1.80 A; B/P=17-37.
DR   PDB; 3IGK; X-ray; 1.70 A; A=94-293.
DR   PDB; 3IGL; X-ray; 1.80 A; A=94-293.
DR   PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291.
DR   PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293.
DR   PDB; 3LW1; X-ray; 1.28 A; P=385-393.
DR   PDB; 3PDH; X-ray; 1.80 A; D=372-389.
DR   PDB; 3SAK; NMR; -; A/B/C/D=319-360.
DR   PDBsum; 1A1U; -.
DR   PDBsum; 1AIE; -.
DR   PDBsum; 1C26; -.
DR   PDBsum; 1DT7; -.
DR   PDBsum; 1GZH; -.
DR   PDBsum; 1H26; -.
DR   PDBsum; 1HS5; -.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1KZY; -.
DR   PDBsum; 1MA3; -.
DR   PDBsum; 1OLG; -.
DR   PDBsum; 1OLH; -.
DR   PDBsum; 1PES; -.
DR   PDBsum; 1PET; -.
DR   PDBsum; 1SAE; -.
DR   PDBsum; 1SAF; -.
DR   PDBsum; 1SAH; -.
DR   PDBsum; 1SAJ; -.
DR   PDBsum; 1SAK; -.
DR   PDBsum; 1SAL; -.
DR   PDBsum; 1TSR; -.
DR   PDBsum; 1TUP; -.
DR   PDBsum; 1UOL; -.
DR   PDBsum; 1XQH; -.
DR   PDBsum; 1YC5; -.
DR   PDBsum; 1YCQ; -.
DR   PDBsum; 1YCR; -.
DR   PDBsum; 1YCS; -.
DR   PDBsum; 2AC0; -.
DR   PDBsum; 2ADY; -.
DR   PDBsum; 2AHI; -.
DR   PDBsum; 2ATA; -.
DR   PDBsum; 2B3G; -.
DR   PDBsum; 2BIM; -.
DR   PDBsum; 2BIN; -.
DR   PDBsum; 2BIO; -.
DR   PDBsum; 2BIP; -.
DR   PDBsum; 2BIQ; -.
DR   PDBsum; 2F1X; -.
DR   PDBsum; 2FEJ; -.
DR   PDBsum; 2FOJ; -.
DR   PDBsum; 2FOO; -.
DR   PDBsum; 2GS0; -.
DR   PDBsum; 2H1L; -.
DR   PDBsum; 2H2D; -.
DR   PDBsum; 2H2F; -.
DR   PDBsum; 2H4F; -.
DR   PDBsum; 2H4H; -.
DR   PDBsum; 2H4J; -.
DR   PDBsum; 2H59; -.
DR   PDBsum; 2J0Z; -.
DR   PDBsum; 2J10; -.
DR   PDBsum; 2J11; -.
DR   PDBsum; 2J1W; -.
DR   PDBsum; 2J1X; -.
DR   PDBsum; 2J1Y; -.
DR   PDBsum; 2J1Z; -.
DR   PDBsum; 2J20; -.
DR   PDBsum; 2J21; -.
DR   PDBsum; 2K8F; -.
DR   PDBsum; 2L14; -.
DR   PDBsum; 2OCJ; -.
DR   PDBsum; 2PCX; -.
DR   PDBsum; 2QVQ; -.
DR   PDBsum; 2QXA; -.
DR   PDBsum; 2QXB; -.
DR   PDBsum; 2QXC; -.
DR   PDBsum; 2VUK; -.
DR   PDBsum; 2WGX; -.
DR   PDBsum; 2X0U; -.
DR   PDBsum; 2X0V; -.
DR   PDBsum; 2X0W; -.
DR   PDBsum; 2Z5S; -.
DR   PDBsum; 2Z5T; -.
DR   PDBsum; 3D05; -.
DR   PDBsum; 3D06; -.
DR   PDBsum; 3D07; -.
DR   PDBsum; 3D08; -.
DR   PDBsum; 3D09; -.
DR   PDBsum; 3D0A; -.
DR   PDBsum; 3DAB; -.
DR   PDBsum; 3DAC; -.
DR   PDBsum; 3IGK; -.
DR   PDBsum; 3IGL; -.
DR   PDBsum; 3KMD; -.
DR   PDBsum; 3KZ8; -.
DR   PDBsum; 3LW1; -.
DR   PDBsum; 3PDH; -.
DR   PDBsum; 3SAK; -.
DR   ProteinModelPortal; P04637; -.
DR   SMR; P04637; 94-291, 319-360.
DR   DisProt; DP00086; -.
DR   DIP; DIP-368N; -.
DR   IntAct; P04637; 375.
DR   MINT; MINT-91013; -.
DR   STRING; P04637; -.
DR   PhosphoSite; P04637; -.
DR   SWISS-2DPAGE; P04637; -.
DR   PRIDE; P04637; -.
DR   Ensembl; ENST00000269305; ENSP00000269305; ENSG00000141510.
DR   Ensembl; ENST00000359597; ENSP00000352610; ENSG00000141510.
DR   Ensembl; ENST00000396473; ENSP00000379735; ENSG00000141510.
DR   Ensembl; ENST00000419024; ENSP00000402130; ENSG00000141510.
DR   Ensembl; ENST00000420246; ENSP00000391127; ENSG00000141510.
DR   Ensembl; ENST00000445888; ENSP00000391478; ENSG00000141510.
DR   Ensembl; ENST00000455263; ENSP00000398846; ENSG00000141510.
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   UCSC; uc002gij.2; human.
DR   CTD; 7157; -.
DR   GeneCards; GC17M007465; -.
DR   HGNC; HGNC:11998; TP53.
DR   HPA; CAB002973; -.
DR   HPA; CAB039238; -.
DR   HPA; CAB039239; -.
DR   MIM; 133239; phenotype.
DR   MIM; 151623; phenotype.
DR   MIM; 191170; gene+phenotype.
DR   MIM; 202300; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 260500; phenotype.
DR   MIM; 275355; phenotype.
DR   neXtProt; NX_P04637; -.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 360; Glioblastoma.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 2807; Papilloma of choroid plexus.
DR   PharmGKB; PA36679; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P04637; -.
DR   OMA; IHYNFMC; -.
DR   OrthoDB; EOG45757H; -.
DR   Pathway_Interaction_DB; aurora_a_pathway; Aurora A signaling.
DR   Pathway_Interaction_DB; bard1pathway; BARD1 signaling events.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; hif1apathway; Hypoxic and oxygen homeostasis regulation of HIF-1-alpha.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Pathway_Interaction_DB; hdac_classiii_pathway; Signaling events mediated by HDAC Class III.
DR   Pathway_Interaction_DB; p38alphabetadownstreampathway; Signaling mediated by p38-alpha and p38-beta.
DR   Reactome; REACT_1538; Cell Cycle Checkpoints.
DR   Reactome; REACT_604; Hemostasis.
DR   PMAP-CutDB; P04637; -.
DR   ArrayExpress; P04637; -.
DR   Bgee; P04637; -.
DR   Genevestigator; P04637; -.
DR   GermOnline; ENSG00000141510; Homo sapiens.
DR   GO; GO:0000785; C:chromatin; ISS:RefGenome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:RefGenome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005626; C:insoluble fraction; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:BHF-UCL.
DR   GO; GO:0043234; C:protein complex; IDA:BHF-UCL.
DR   GO; GO:0005657; C:replication fork; ISS:RefGenome.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; ISS:RefGenome.
DR   GO; GO:0000739; F:DNA strand annealing activity; IDA:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; ISS:RefGenome.
DR   GO; GO:0010843; ?:promoter binding; IDA:BHF-UCL.
DR   GO; GO:0010843; ?:promoter binding; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0016566; ?:specific transcriptional repressor activity; ISS:BHF-UCL.
DR   GO; GO:0016563; ?:transcription activator activity; IMP:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB.
DR   GO; GO:0008635; P:activation of caspase activity by cytochrome c; IDA:UniProtKB.
DR   GO; GO:0006284; P:base-excision repair; TAS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0034613; P:cellular protein localization; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IEP:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:MGI.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL.
DR   GO; GO:0034644; P:cellular response to UV; ISS:RefGenome.
DR   GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0042771; P:DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; IDA:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IMP:BHF-UCL.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0043066; P:negative regulation of apoptosis; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0010553; ?:?; ISS:BHF-UCL.
DR   GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL.
DR   GO; GO:0010552; ?:?; IDA:BHF-UCL.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; ISS:RefGenome.
DR   GO; GO:0043525; P:positive regulation of neuron apoptosis; ISS:RefGenome.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptosis; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0008104; P:protein localization; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; TAS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permeability; TAS:UniProtKB.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL.
DR   GO; GO:0010165; P:response to X-ray; ISS:RefGenome.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   Gene3D; G3DSA:2.60.40.720; p53_RUNT_DNA_bd; 1.
DR   Gene3D; G3DSA:4.10.170.10; p53_tetrameristn; 1.
DR   PANTHER; PTHR11447; Trp53; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; P53_like_DNA_bnd; 1.
DR   SUPFAM; SSF47719; p53_tetrameristn; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Cell cycle; Complete proteome;
KW   Cytoplasm; Disease mutation; DNA-binding; Endoplasmic reticulum;
KW   Glycoprotein; Host-virus interaction; Isopeptide bond;
KW   Li-Fraumeni syndrome; Metal-binding; Methylation; Nucleus;
KW   Phosphoprotein; Polymorphism; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185703.
FT   DNA_BIND    102    292
FT   REGION        1     83       Interaction with HRMT1L2.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX.
FT   REGION      100    370       Interaction with HIPK1 (By similarity).
FT   REGION      113    236       Required for interaction with FBXO42.
FT   REGION      116    292       Interaction with AXIN1 (By similarity).
FT   REGION      241    248       Interacts with the 53BP2 SH3 domain.
FT   REGION      256    294       Interaction with E4F1.
FT   REGION      273    280       Interaction with DNA.
FT   REGION      300    393       Interaction with CARM1.
FT   REGION      319    360       Interaction with HIPK2.
FT   REGION      325    356       Oligomerization.
FT   REGION      359    363       Interaction with USP7.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF        17     25       TADI.
FT   MOTIF        48     56       TADII.
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT   MOTIF       339    350       Nuclear export signal.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc.
FT   METAL       179    179       Zinc.
FT   METAL       238    238       Zinc.
FT   METAL       242    242       Zinc.
FT   SITE        120    120       Interaction with DNA.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4.
FT   MOD_RES      15     15       Phosphoserine; by PRPK and ATM.
FT   MOD_RES      18     18       Phosphothreonine; by VRK1.
FT   MOD_RES      20     20       Phosphoserine; by CHK2.
FT   MOD_RES      46     46       Phosphoserine; by HIPK2.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1.
FT   MOD_RES      99     99       Phosphoserine.
FT   MOD_RES     292    292       N6-acetyllysine.
FT   MOD_RES     305    305       N6-acetyllysine.
FT   MOD_RES     313    313       Phosphoserine.
FT   MOD_RES     314    314       Phosphoserine.
FT   MOD_RES     315    315       Phosphoserine; by CDK1.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT   MOD_RES     381    381       N6-acetyllysine.
FT   MOD_RES     382    382       N6-acetyllysine; alternate.
FT   MOD_RES     382    382       N6-methyllysine; by SETD8; alternate.
FT   MOD_RES     392    392       Phosphoserine; by CK2.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   VAR_SEQ       1    132       Missing (in isoform 7, isoform 8 and
FT                                isoform 9).
FT                                /FTId=VSP_040833.
FT   VAR_SEQ       1     39       Missing (in isoform 4, isoform 5 and
FT                                isoform 6).
FT                                /FTId=VSP_040832.
FT   VAR_SEQ     332    346       IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in
FT                                isoform 3, isoform 6 and isoform 9).
FT                                /FTId=VSP_040560.
FT   VAR_SEQ     332    341       IRGRERFEMF -> DQTSFQKENC (in isoform 2,
FT                                isoform 5 and isoform 8).
FT                                /FTId=VSP_006535.
FT   VAR_SEQ     342    393       Missing (in isoform 2, isoform 5 and
FT                                isoform 8).
FT                                /FTId=VSP_006536.
FT   VAR_SEQ     347    393       Missing (in isoform 3, isoform 6 and
FT                                isoform 9).
FT                                /FTId=VSP_040561.
FT   VARIANT       5      5       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044543.
FT   VARIANT       6      6       S -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044544.
FT   VARIANT       7      7       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005851.
FT   VARIANT       8      8       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044545.
FT   VARIANT      10     10       V -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044546.
FT   VARIANT      11     11       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044547.
FT   VARIANT      11     11       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044548.
FT   VARIANT      15     15       S -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044549.
FT   VARIANT      16     16       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044550.
FT   VARIANT      17     17       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044551.
FT   VARIANT      24     24       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044552.
FT   VARIANT      28     28       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044553.
FT   VARIANT      29     30       NN -> KD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047158.
FT   VARIANT      31     31       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044554.
FT   VARIANT      33     33       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044555.
FT   VARIANT      34     34       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044556.
FT   VARIANT      35     35       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005852.
FT   VARIANT      36     36       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044557.
FT   VARIANT      37     37       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044558.
FT   VARIANT      37     37       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044559.
FT   VARIANT      39     39       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044560.
FT   VARIANT      39     39       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044561.
FT   VARIANT      42     42       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044562.
FT   VARIANT      43     43       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005853.
FT   VARIANT      44     44       M -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044563.
FT   VARIANT      44     44       M -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044564.
FT   VARIANT      44     44       M -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044565.
FT   VARIANT      45     45       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044566.
FT   VARIANT      46     46       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044567.
FT   VARIANT      46     46       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044568.
FT   VARIANT      47     47       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044569.
FT   VARIANT      47     47       P -> S (in dbSNP:rs1800371).
FT                                /FTId=VAR_014632.
FT   VARIANT      48     48       D -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044570.
FT   VARIANT      49     49       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044571.
FT   VARIANT      49     49       D -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044572.
FT   VARIANT      49     49       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044573.
FT   VARIANT      52     52       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044574.
FT   VARIANT      53     53       W -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005854.
FT   VARIANT      53     53       W -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044575.
FT   VARIANT      54     54       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044576.
FT   VARIANT      54     54       F -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044577.
FT   VARIANT      56     56       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044578.
FT   VARIANT      56     56       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044579.
FT   VARIANT      58     58       P -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044580.
FT   VARIANT      58     58       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044581.
FT   VARIANT      59     59       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044582.
FT   VARIANT      59     59       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044583.
FT   VARIANT      59     59       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045783.
FT   VARIANT      60     60       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044584.
FT   VARIANT      60     60       P -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044585.
FT   VARIANT      60     60       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005855.
FT   VARIANT      61     61       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044586.
FT   VARIANT      61     61       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044587.
FT   VARIANT      62     62       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044588.
FT   VARIANT      63     63       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044589.
FT   VARIANT      63     63       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044590.
FT   VARIANT      65     65       R -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044591.
FT   VARIANT      66     66       M -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044592.
FT   VARIANT      66     66       M -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044593.
FT   VARIANT      67     67       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044594.
FT   VARIANT      67     67       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044595.
FT   VARIANT      67     67       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044596.
FT   VARIANT      68     68       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044597.
FT   VARIANT      68     68       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044598.
FT   VARIANT      69     69       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044599.
FT   VARIANT      69     69       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044600.
FT   VARIANT      69     69       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044601.
FT   VARIANT      69     69       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044602.
FT   VARIANT      70     70       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044603.
FT   VARIANT      71     71       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044604.
FT   VARIANT      72     72       P -> C (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045784.
FT   VARIANT      72     72       P -> G (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045785.
FT   VARIANT      72     72       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045786.
FT   VARIANT      72     72       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045787.
FT   VARIANT      72     72       P -> R (in dbSNP:rs1042522).
FT                                /FTId=VAR_005856.
FT   VARIANT      73     73       V -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044605.
FT   VARIANT      73     73       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044606.
FT   VARIANT      73     73       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044607.
FT   VARIANT      74     74       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044608.
FT   VARIANT      75     75       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044609.
FT   VARIANT      75     75       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044610.
FT   VARIANT      75     75       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044611.
FT   VARIANT      76     76       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044612.
FT   VARIANT      76     76       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044613.
FT   VARIANT      77     77       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044614.
FT   VARIANT      78     78       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044615.
FT   VARIANT      79     79       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044616.
FT   VARIANT      79     79       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005857.
FT   VARIANT      79     79       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044617.
FT   VARIANT      80     80       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044618.
FT   VARIANT      80     80       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044619.
FT   VARIANT      81     81       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044620.
FT   VARIANT      82     82       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044621.
FT   VARIANT      82     82       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044622.
FT   VARIANT      83     83       A -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044623.
FT   VARIANT      83     83       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044624.
FT   VARIANT      84     84       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044625.
FT   VARIANT      84     84       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044626.
FT   VARIANT      85     85       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044627.
FT   VARIANT      85     85       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044628.
FT   VARIANT      86     86       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044629.
FT   VARIANT      87     87       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005858.
FT   VARIANT      88     88       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044630.
FT   VARIANT      88     88       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044631.
FT   VARIANT      89     89       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044632.
FT   VARIANT      89     89       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044633.
FT   VARIANT      90     90       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044634.
FT   VARIANT      90     90       S -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044635.
FT   VARIANT      91     91       W -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044636.
FT   VARIANT      92     92       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044637.
FT   VARIANT      92     92       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044638.
FT   VARIANT      92     92       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044639.
FT   VARIANT      93     93       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044640.
FT   VARIANT      93     93       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044641.
FT   VARIANT      94     94       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044642.
FT   VARIANT      94     94       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005859.
FT   VARIANT      95     95       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044643.
FT   VARIANT      95     95       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044644.
FT   VARIANT      96     96       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044645.
FT   VARIANT      96     96       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044646.
FT   VARIANT      96     96       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044647.
FT   VARIANT      97     97       V -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044648.
FT   VARIANT      97     97       V -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044649.
FT   VARIANT      97     97       V -> I (in familial cancer not matching
FT                                LFS; germline mutation and in a sporadic
FT                                cancer; somatic mutation).
FT                                /FTId=VAR_044650.
FT   VARIANT      98     98       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044651.
FT   VARIANT      98     98       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044652.
FT   VARIANT      99     99       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044653.
FT   VARIANT      99     99       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044654.
FT   VARIANT     100    100       Q -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044655.
FT   VARIANT     101    101       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044656.
FT   VARIANT     101    101       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044657.
FT   VARIANT     102    102       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044658.
FT   VARIANT     104    104       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044659.
FT   VARIANT     104    104       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044660.
FT   VARIANT     105    105       G -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044661.
FT   VARIANT     105    105       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044662.
FT   VARIANT     105    105       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044663.
FT   VARIANT     105    105       G -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044664.
FT   VARIANT     105    105       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044665.
FT   VARIANT     106    106       S -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044666.
FT   VARIANT     106    106       S -> R (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044667.
FT   VARIANT     107    107       Y -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044668.
FT   VARIANT     107    107       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044669.
FT   VARIANT     107    107       Y -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044670.
FT   VARIANT     108    108       G -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044671.
FT   VARIANT     108    108       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044672.
FT   VARIANT     109    109       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044673.
FT   VARIANT     109    109       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044674.
FT   VARIANT     109    109       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044675.
FT   VARIANT     110    110       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005860.
FT   VARIANT     110    110       R -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044676.
FT   VARIANT     110    110       R -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044677.
FT   VARIANT     110    110       R -> L (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_005861.
FT   VARIANT     110    110       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11540654).
FT                                /FTId=VAR_005862.
FT   VARIANT     110    110       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044678.
FT   VARIANT     111    111       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044679.
FT   VARIANT     111    111       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044680.
FT   VARIANT     111    111       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044681.
FT   VARIANT     111    111       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044682.
FT   VARIANT     112    112       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044683.
FT   VARIANT     112    112       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044684.
FT   VARIANT     113    113       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005863.
FT   VARIANT     113    113       F -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045788.
FT   VARIANT     113    113       F -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044685.
FT   VARIANT     113    113       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044686.
FT   VARIANT     113    113       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044687.
FT   VARIANT     113    113       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033033.
FT   VARIANT     115    115       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044688.
FT   VARIANT     116    116       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044689.
FT   VARIANT     116    116       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044690.
FT   VARIANT     116    116       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044691.
FT   VARIANT     117    117       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044692.
FT   VARIANT     117    117       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044693.
FT   VARIANT     118    118       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044694.
FT   VARIANT     118    118       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044695.
FT   VARIANT     118    118       T -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044696.
FT   VARIANT     119    119       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044697.
FT   VARIANT     119    119       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044698.
FT   VARIANT     120    120       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044699.
FT   VARIANT     120    120       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044700.
FT   VARIANT     120    120       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044701.
FT   VARIANT     120    120       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044702.
FT   VARIANT     121    121       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044703.
FT   VARIANT     122    122       V -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044704.
FT   VARIANT     123    123       T -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044705.
FT   VARIANT     123    123       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044706.
FT   VARIANT     124    124       C -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044707.
FT   VARIANT     124    124       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044708.
FT   VARIANT     124    124       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044709.
FT   VARIANT     124    124       C -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044710.
FT   VARIANT     124    124       C -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044711.
FT   VARIANT     125    125       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044712.
FT   VARIANT     125    125       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044713.
FT   VARIANT     125    125       T -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005864.
FT   VARIANT     125    125       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044714.
FT   VARIANT     125    125       T -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044715.
FT   VARIANT     126    126       Y -> C (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044716.
FT   VARIANT     126    126       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005865.
FT   VARIANT     126    126       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044717.
FT   VARIANT     126    126       Y -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045789.
FT   VARIANT     126    126       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044718.
FT   VARIANT     126    126       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005866.
FT   VARIANT     126    126       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044719.
FT   VARIANT     127    127       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044720.
FT   VARIANT     127    127       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005867.
FT   VARIANT     127    127       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044721.
FT   VARIANT     127    127       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044722.
FT   VARIANT     127    127       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044723.
FT   VARIANT     128    128       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044724.
FT   VARIANT     128    128       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044725.
FT   VARIANT     128    128       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044726.
FT   VARIANT     128    128       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005868.
FT   VARIANT     129    129       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005869.
FT   VARIANT     129    129       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044727.
FT   VARIANT     129    129       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044728.
FT   VARIANT     129    129       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044729.
FT   VARIANT     130    130       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044730.
FT   VARIANT     130    130       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044731.
FT   VARIANT     130    130       L -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044732.
FT   VARIANT     130    130       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044733.
FT   VARIANT     130    130       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005870.
FT   VARIANT     130    130       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044734.
FT   VARIANT     131    131       N -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044735.
FT   VARIANT     131    131       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044736.
FT   VARIANT     131    131       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044737.
FT   VARIANT     131    131       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005872.
FT   VARIANT     131    131       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005871.
FT   VARIANT     131    131       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044738.
FT   VARIANT     131    131       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044739.
FT   VARIANT     132    133       KM -> NL (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047159.
FT   VARIANT     132    132       K -> E (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044740.
FT   VARIANT     132    132       K -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045790.
FT   VARIANT     132    132       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005873.
FT   VARIANT     132    132       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044741.
FT   VARIANT     132    132       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005874.
FT   VARIANT     132    132       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044742.
FT   VARIANT     132    132       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044743.
FT   VARIANT     132    132       K -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045791.
FT   VARIANT     133    133       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044744.
FT   VARIANT     133    133       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044745.
FT   VARIANT     133    133       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044746.
FT   VARIANT     133    133       M -> R (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044747.
FT   VARIANT     133    133       M -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934873).
FT                                /FTId=VAR_005875.
FT   VARIANT     133    133       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044748.
FT   VARIANT     134    134       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044749.
FT   VARIANT     134    134       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044750.
FT   VARIANT     134    134       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_036504.
FT   VARIANT     134    134       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044751.
FT   VARIANT     134    134       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044752.
FT   VARIANT     135    135       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005877.
FT   VARIANT     135    135       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044753.
FT   VARIANT     135    135       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044754.
FT   VARIANT     135    135       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005876.
FT   VARIANT     135    135       C -> T (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045792.
FT   VARIANT     135    135       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044755.
FT   VARIANT     135    135       C -> Y (in sporadic cancers; somatic
FT                                mutation; decreased E6-mediated binding
FT                                to E6-AP).
FT                                /FTId=VAR_044756.
FT   VARIANT     136    136       Q -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005878.
FT   VARIANT     136    136       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044757.
FT   VARIANT     136    136       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005879.
FT   VARIANT     136    136       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044758.
FT   VARIANT     136    136       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044759.
FT   VARIANT     137    137       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044760.
FT   VARIANT     137    137       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044761.
FT   VARIANT     137    137       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005880.
FT   VARIANT     137    137       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044762.
FT   VARIANT     138    138       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044763.
FT   VARIANT     138    138       A -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934875).
FT                                /FTId=VAR_005881.
FT   VARIANT     138    138       A -> S (in LFS; germline mutation).
FT                                /FTId=VAR_044764.
FT   VARIANT     138    138       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044765.
FT   VARIANT     138    138       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033034.
FT   VARIANT     139    139       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044766.
FT   VARIANT     139    139       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005882.
FT   VARIANT     139    139       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044767.
FT   VARIANT     139    139       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044768.
FT   VARIANT     139    139       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044769.
FT   VARIANT     140    140       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044770.
FT   VARIANT     140    140       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044771.
FT   VARIANT     140    140       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044772.
FT   VARIANT     140    140       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044773.
FT   VARIANT     140    140       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044774.
FT   VARIANT     141    141       C -> A (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045793.
FT   VARIANT     141    141       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005885.
FT   VARIANT     141    141       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005884.
FT   VARIANT     141    141       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044775.
FT   VARIANT     141    141       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044776.
FT   VARIANT     141    141       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044777.
FT   VARIANT     141    141       C -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005886.
FT   VARIANT     142    142       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044778.
FT   VARIANT     142    142       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045794.
FT   VARIANT     142    142       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044779.
FT   VARIANT     142    142       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044780.
FT   VARIANT     142    142       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044781.
FT   VARIANT     142    142       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044782.
FT   VARIANT     142    142       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044783.
FT   VARIANT     143    143       V -> A (in sporadic cancers; somatic
FT                                mutation; strong DNA binding ability at
FT                                32.5 degrees Celsius; strong reduction of
FT                                transcriptional activity at 37.5 degrees
FT                                Celsius).
FT                                /FTId=VAR_005887.
FT   VARIANT     143    143       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044784.
FT   VARIANT     143    143       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044785.
FT   VARIANT     143    143       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044786.
FT   VARIANT     143    143       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044787.
FT   VARIANT     144    144       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044788.
FT   VARIANT     144    144       Q -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044789.
FT   VARIANT     144    144       Q -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044790.
FT   VARIANT     144    144       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005888.
FT   VARIANT     144    144       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044791.
FT   VARIANT     145    145       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044792.
FT   VARIANT     145    145       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005889.
FT   VARIANT     145    145       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005890.
FT   VARIANT     145    145       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044793.
FT   VARIANT     145    145       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044794.
FT   VARIANT     146    146       W -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044795.
FT   VARIANT     146    146       W -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044796.
FT   VARIANT     146    146       W -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044797.
FT   VARIANT     146    146       W -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044798.
FT   VARIANT     146    146       W -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044799.
FT   VARIANT     147    147       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044800.
FT   VARIANT     147    147       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005891.
FT   VARIANT     147    147       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044801.
FT   VARIANT     147    147       V -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044802.
FT   VARIANT     147    147       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005892.
FT   VARIANT     147    147       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044803.
FT   VARIANT     148    148       D -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044804.
FT   VARIANT     148    148       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044805.
FT   VARIANT     148    148       D -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044806.
FT   VARIANT     148    148       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044807.
FT   VARIANT     148    148       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044808.
FT   VARIANT     148    148       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044809.
FT   VARIANT     149    149       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044810.
FT   VARIANT     149    149       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005893.
FT   VARIANT     149    149       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044811.
FT   VARIANT     150    150       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044812.
FT   VARIANT     150    150       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044813.
FT   VARIANT     150    150       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044814.
FT   VARIANT     150    150       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044815.
FT   VARIANT     150    150       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044816.
FT   VARIANT     150    150       T -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044817.
FT   VARIANT     151    151       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005894.
FT   VARIANT     151    151       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044818.
FT   VARIANT     151    151       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044819.
FT   VARIANT     151    151       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044820.
FT   VARIANT     151    151       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934874).
FT                                /FTId=VAR_005895.
FT   VARIANT     151    151       P -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005896.
FT   VARIANT     152    152       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044821.
FT   VARIANT     152    152       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005897.
FT   VARIANT     152    152       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044822.
FT   VARIANT     152    152       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044823.
FT   VARIANT     152    152       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005898.
FT   VARIANT     152    152       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044824.
FT   VARIANT     153    153       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044825.
FT   VARIANT     153    153       P -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045795.
FT   VARIANT     153    153       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044826.
FT   VARIANT     153    153       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044827.
FT   VARIANT     153    153       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044828.
FT   VARIANT     153    153       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044829.
FT   VARIANT     153    153       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005899.
FT   VARIANT     154    154       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044830.
FT   VARIANT     154    154       G -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044831.
FT   VARIANT     154    154       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044832.
FT   VARIANT     154    154       G -> I (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045796.
FT   VARIANT     154    154       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044833.
FT   VARIANT     154    154       G -> V (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005900.
FT   VARIANT     155    155       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005901.
FT   VARIANT     155    155       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044834.
FT   VARIANT     155    155       T -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044835.
FT   VARIANT     155    155       T -> N (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044836.
FT   VARIANT     155    155       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044837.
FT   VARIANT     155    155       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044838.
FT   VARIANT     156    156       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044839.
FT   VARIANT     156    156       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044840.
FT   VARIANT     156    156       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044841.
FT   VARIANT     156    156       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044842.
FT   VARIANT     156    156       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005902.
FT   VARIANT     156    156       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044843.
FT   VARIANT     157    157       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044844.
FT   VARIANT     157    157       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005903.
FT   VARIANT     157    157       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005904.
FT   VARIANT     157    157       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044845.
FT   VARIANT     157    157       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_012977.
FT   VARIANT     157    157       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044846.
FT   VARIANT     158    158       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005905.
FT   VARIANT     158    158       R -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045797.
FT   VARIANT     158    158       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005906.
FT   VARIANT     158    158       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005907.
FT   VARIANT     158    158       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044847.
FT   VARIANT     158    158       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044848.
FT   VARIANT     158    158       R -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044849.
FT   VARIANT     158    158       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044850.
FT   VARIANT     158    158       R -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045798.
FT   VARIANT     159    159       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044851.
FT   VARIANT     159    159       A -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045799.
FT   VARIANT     159    159       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044852.
FT   VARIANT     159    159       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044853.
FT   VARIANT     159    159       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044854.
FT   VARIANT     159    159       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044855.
FT   VARIANT     159    159       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044856.
FT   VARIANT     160    161       MA -> IP (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047160.
FT   VARIANT     160    161       MA -> IS (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047161.
FT   VARIANT     160    161       MA -> IT (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047162.
FT   VARIANT     160    160       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005908.
FT   VARIANT     160    160       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044857.
FT   VARIANT     160    160       M -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044858.
FT   VARIANT     160    160       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044859.
FT   VARIANT     161    161       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044860.
FT   VARIANT     161    161       A -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045800.
FT   VARIANT     161    161       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044861.
FT   VARIANT     161    161       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044862.
FT   VARIANT     161    161       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005909.
FT   VARIANT     161    161       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044863.
FT   VARIANT     161    161       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044864.
FT   VARIANT     162    162       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044865.
FT   VARIANT     162    162       I -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044866.
FT   VARIANT     162    162       I -> N (in a breast cancer with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044867.
FT   VARIANT     162    162       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005910.
FT   VARIANT     162    162       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044868.
FT   VARIANT     162    162       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005911.
FT   VARIANT     163    163       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_033035.
FT   VARIANT     163    163       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044869.
FT   VARIANT     163    163       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044870.
FT   VARIANT     163    163       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005912.
FT   VARIANT     163    163       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044871.
FT   VARIANT     163    163       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044872.
FT   VARIANT     164    164       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044873.
FT   VARIANT     164    164       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044874.
FT   VARIANT     164    164       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005913.
FT   VARIANT     164    164       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005914.
FT   VARIANT     164    164       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044875.
FT   VARIANT     164    164       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044876.
FT   VARIANT     165    165       Q -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044877.
FT   VARIANT     165    165       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044878.
FT   VARIANT     165    165       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005915.
FT   VARIANT     165    165       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044879.
FT   VARIANT     165    165       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005916.
FT   VARIANT     166    166       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044880.
FT   VARIANT     166    166       S -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044881.
FT   VARIANT     166    166       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005917.
FT   VARIANT     166    166       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044882.
FT   VARIANT     166    166       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044883.
FT   VARIANT     167    168       QH -> HD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047163.
FT   VARIANT     167    168       QH -> YL (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047164.
FT   VARIANT     167    167       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044884.
FT   VARIANT     167    167       Q -> K (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_044885.
FT   VARIANT     167    167       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044886.
FT   VARIANT     167    167       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044887.
FT   VARIANT     168    169       HM -> LI (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047165.
FT   VARIANT     168    168       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044888.
FT   VARIANT     168    168       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044889.
FT   VARIANT     168    168       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044890.
FT   VARIANT     168    168       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044891.
FT   VARIANT     168    168       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044892.
FT   VARIANT     168    168       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005918.
FT   VARIANT     168    168       H -> V (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045801.
FT   VARIANT     168    168       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044893.
FT   VARIANT     169    170       MT -> IS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047166.
FT   VARIANT     169    169       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005919.
FT   VARIANT     169    169       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044894.
FT   VARIANT     169    169       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005920.
FT   VARIANT     169    169       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044895.
FT   VARIANT     170    170       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044896.
FT   VARIANT     170    170       T -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044897.
FT   VARIANT     170    170       T -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005921.
FT   VARIANT     170    170       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044898.
FT   VARIANT     170    170       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005922.
FT   VARIANT     171    171       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044899.
FT   VARIANT     171    171       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044900.
FT   VARIANT     171    171       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044901.
FT   VARIANT     171    171       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044902.
FT   VARIANT     171    171       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044903.
FT   VARIANT     171    171       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044904.
FT   VARIANT     172    172       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005923.
FT   VARIANT     172    172       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044905.
FT   VARIANT     172    172       V -> F (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044906.
FT   VARIANT     172    172       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044907.
FT   VARIANT     172    172       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044908.
FT   VARIANT     173    173       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044909.
FT   VARIANT     173    173       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005924.
FT   VARIANT     173    173       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044910.
FT   VARIANT     173    173       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005925.
FT   VARIANT     173    173       V -> M (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005926.
FT   VARIANT     173    173       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045802.
FT   VARIANT     174    174       R -> G (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_044911.
FT   VARIANT     174    174       R -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005927.
FT   VARIANT     174    174       R -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044912.
FT   VARIANT     174    174       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044913.
FT   VARIANT     174    174       R -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044914.
FT   VARIANT     174    174       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044915.
FT   VARIANT     175    175       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005928.
FT   VARIANT     175    175       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005929.
FT   VARIANT     175    175       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934578).
FT                                /FTId=VAR_005932.
FT   VARIANT     175    175       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005930.
FT   VARIANT     175    175       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005931.
FT   VARIANT     175    175       R -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044916.
FT   VARIANT     175    175       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044917.
FT   VARIANT     176    177       CP -> FS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047167.
FT   VARIANT     176    176       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005933.
FT   VARIANT     176    176       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044918.
FT   VARIANT     176    176       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044919.
FT   VARIANT     176    176       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044920.
FT   VARIANT     176    176       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005934.
FT   VARIANT     176    176       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044921.
FT   VARIANT     177    177       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044922.
FT   VARIANT     177    177       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045803.
FT   VARIANT     177    177       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044923.
FT   VARIANT     177    177       P -> I (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045804.
FT   VARIANT     177    177       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005935.
FT   VARIANT     177    177       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_036505.
FT   VARIANT     177    177       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044924.
FT   VARIANT     177    177       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044925.
FT   VARIANT     178    179       HH -> QS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047168.
FT   VARIANT     178    178       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044926.
FT   VARIANT     178    178       H -> HPHP (in a Burkitt lymphoma).
FT                                /FTId=VAR_005936.
FT   VARIANT     178    178       H -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044927.
FT   VARIANT     178    178       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044928.
FT   VARIANT     178    178       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044929.
FT   VARIANT     178    178       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044930.
FT   VARIANT     178    178       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044931.
FT   VARIANT     178    178       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044932.
FT   VARIANT     179    179       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044933.
FT   VARIANT     179    179       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044934.
FT   VARIANT     179    179       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044935.
FT   VARIANT     179    179       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044936.
FT   VARIANT     179    179       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044937.
FT   VARIANT     179    179       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044938.
FT   VARIANT     179    179       H -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044939.
FT   VARIANT     180    180       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044940.
FT   VARIANT     180    180       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044941.
FT   VARIANT     180    180       E -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044942.
FT   VARIANT     180    180       E -> K (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044943.
FT   VARIANT     180    180       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044944.
FT   VARIANT     180    180       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044945.
FT   VARIANT     181    181       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044946.
FT   VARIANT     181    181       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044947.
FT   VARIANT     181    181       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044948.
FT   VARIANT     181    181       R -> L (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_005937.
FT   VARIANT     181    181       R -> P (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044949.
FT   VARIANT     181    181       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044950.
FT   VARIANT     182    182       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044951.
FT   VARIANT     182    182       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005938.
FT   VARIANT     182    182       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044952.
FT   VARIANT     183    183       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044953.
FT   VARIANT     183    183       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044954.
FT   VARIANT     184    184       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044955.
FT   VARIANT     184    184       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044956.
FT   VARIANT     184    184       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047169.
FT   VARIANT     184    184       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044957.
FT   VARIANT     184    184       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005939.
FT   VARIANT     185    185       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044958.
FT   VARIANT     185    185       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044959.
FT   VARIANT     185    185       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044960.
FT   VARIANT     185    185       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044961.
FT   VARIANT     185    185       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044962.
FT   VARIANT     185    185       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044963.
FT   VARIANT     186    186       D -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044964.
FT   VARIANT     186    186       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044965.
FT   VARIANT     186    186       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044966.
FT   VARIANT     186    186       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044967.
FT   VARIANT     186    186       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044968.
FT   VARIANT     186    186       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005940.
FT   VARIANT     187    187       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005941.
FT   VARIANT     187    187       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044969.
FT   VARIANT     187    187       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045805.
FT   VARIANT     187    187       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044970.
FT   VARIANT     187    187       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005942.
FT   VARIANT     187    187       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044971.
FT   VARIANT     188    188       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044972.
FT   VARIANT     188    188       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044973.
FT   VARIANT     189    189       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044974.
FT   VARIANT     189    189       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044975.
FT   VARIANT     189    189       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005943.
FT   VARIANT     189    189       A -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044976.
FT   VARIANT     189    189       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044977.
FT   VARIANT     189    189       A -> V (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044978.
FT   VARIANT     190    190       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044979.
FT   VARIANT     190    190       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044980.
FT   VARIANT     190    190       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005944.
FT   VARIANT     190    190       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044981.
FT   VARIANT     190    190       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044982.
FT   VARIANT     190    190       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044983.
FT   VARIANT     191    191       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044984.
FT   VARIANT     191    191       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044985.
FT   VARIANT     191    191       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044986.
FT   VARIANT     191    191       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044987.
FT   VARIANT     191    191       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005945.
FT   VARIANT     192    193       QH -> HN (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047170.
FT   VARIANT     192    193       QH -> HY (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047171.
FT   VARIANT     192    192       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044988.
FT   VARIANT     192    192       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044989.
FT   VARIANT     192    192       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044990.
FT   VARIANT     192    192       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044991.
FT   VARIANT     192    192       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005946.
FT   VARIANT     193    193       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005947.
FT   VARIANT     193    193       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044992.
FT   VARIANT     193    193       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044993.
FT   VARIANT     193    193       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044994.
FT   VARIANT     193    193       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044995.
FT   VARIANT     193    193       H -> R (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005948.
FT   VARIANT     193    193       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044996.
FT   VARIANT     194    194       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044997.
FT   VARIANT     194    194       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044998.
FT   VARIANT     194    194       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044999.
FT   VARIANT     194    194       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005949.
FT   VARIANT     194    194       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005950.
FT   VARIANT     194    194       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045000.
FT   VARIANT     195    195       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045001.
FT   VARIANT     195    195       I -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047172.
FT   VARIANT     195    195       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045002.
FT   VARIANT     195    195       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045003.
FT   VARIANT     195    195       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005951.
FT   VARIANT     195    195       I -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045004.
FT   VARIANT     195    195       I -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045806.
FT   VARIANT     196    196       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045005.
FT   VARIANT     196    196       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045006.
FT   VARIANT     196    196       R -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045007.
FT   VARIANT     196    196       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045008.
FT   VARIANT     196    196       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045009.
FT   VARIANT     197    197       V -> E (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045010.
FT   VARIANT     197    197       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045011.
FT   VARIANT     197    197       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045012.
FT   VARIANT     197    197       V -> M (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045013.
FT   VARIANT     198    198       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045014.
FT   VARIANT     198    198       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045015.
FT   VARIANT     198    198       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005952.
FT   VARIANT     198    198       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045016.
FT   VARIANT     198    198       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045017.
FT   VARIANT     199    199       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045018.
FT   VARIANT     199    199       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045019.
FT   VARIANT     199    199       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045020.
FT   VARIANT     199    199       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045021.
FT   VARIANT     200    200       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045022.
FT   VARIANT     200    200       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045023.
FT   VARIANT     200    200       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045024.
FT   VARIANT     200    200       N -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045807.
FT   VARIANT     200    200       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045025.
FT   VARIANT     200    200       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045026.
FT   VARIANT     201    202       LR -> FC (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047173.
FT   VARIANT     201    201       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045027.
FT   VARIANT     201    201       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045028.
FT   VARIANT     201    201       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045029.
FT   VARIANT     202    202       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045030.
FT   VARIANT     202    202       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045031.
FT   VARIANT     202    202       R -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045032.
FT   VARIANT     202    202       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045033.
FT   VARIANT     202    202       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045034.
FT   VARIANT     202    202       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045035.
FT   VARIANT     203    204       VE -> LV (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047174.
FT   VARIANT     203    203       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045036.
FT   VARIANT     203    203       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045037.
FT   VARIANT     203    203       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045038.
FT   VARIANT     203    203       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045039.
FT   VARIANT     203    203       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045808.
FT   VARIANT     204    204       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045040.
FT   VARIANT     204    204       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045041.
FT   VARIANT     204    204       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045042.
FT   VARIANT     204    204       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045043.
FT   VARIANT     204    204       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045044.
FT   VARIANT     204    204       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045045.
FT   VARIANT     205    205       Y -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005953.
FT   VARIANT     205    205       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005954.
FT   VARIANT     205    205       Y -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047175.
FT   VARIANT     205    205       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045046.
FT   VARIANT     205    205       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045047.
FT   VARIANT     205    205       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045048.
FT   VARIANT     206    206       L -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045049.
FT   VARIANT     206    206       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045050.
FT   VARIANT     207    208       DD -> EY (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047176.
FT   VARIANT     207    207       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045051.
FT   VARIANT     207    207       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045052.
FT   VARIANT     207    207       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045053.
FT   VARIANT     207    207       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045054.
FT   VARIANT     207    207       D -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045055.
FT   VARIANT     207    207       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045056.
FT   VARIANT     208    208       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045057.
FT   VARIANT     208    208       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045058.
FT   VARIANT     208    208       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045059.
FT   VARIANT     208    208       D -> I (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045809.
FT   VARIANT     208    208       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045060.
FT   VARIANT     208    208       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045061.
FT   VARIANT     208    208       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045062.
FT   VARIANT     209    209       R -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045063.
FT   VARIANT     209    209       R -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045064.
FT   VARIANT     209    209       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045065.
FT   VARIANT     209    209       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045066.
FT   VARIANT     210    210       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045067.
FT   VARIANT     210    210       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045068.
FT   VARIANT     210    210       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045069.
FT   VARIANT     210    210       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045070.
FT   VARIANT     210    210       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045071.
FT   VARIANT     210    210       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045072.
FT   VARIANT     210    210       N -> Y (in a familial cancer not matching
FT                                LFS; germline mutation).
FT                                /FTId=VAR_045073.
FT   VARIANT     211    211       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045074.
FT   VARIANT     211    211       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045075.
FT   VARIANT     211    211       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045076.
FT   VARIANT     211    211       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045077.
FT   VARIANT     211    211       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045078.
FT   VARIANT     212    212       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045079.
FT   VARIANT     212    212       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045080.
FT   VARIANT     212    212       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045081.
FT   VARIANT     212    212       F -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045082.
FT   VARIANT     212    212       F -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045083.
FT   VARIANT     213    213       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045084.
FT   VARIANT     213    213       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045085.
FT   VARIANT     213    213       R -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_036506.
FT   VARIANT     213    213       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005955.
FT   VARIANT     213    213       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045086.
FT   VARIANT     214    214       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045087.
FT   VARIANT     214    214       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045088.
FT   VARIANT     214    214       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047177.
FT   VARIANT     214    214       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045089.
FT   VARIANT     214    214       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045090.
FT   VARIANT     215    215       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045091.
FT   VARIANT     215    215       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045092.
FT   VARIANT     215    215       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045093.
FT   VARIANT     215    215       S -> K (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045810.
FT   VARIANT     215    215       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045094.
FT   VARIANT     215    215       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045095.
FT   VARIANT     215    215       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045096.
FT   VARIANT     216    216       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045097.
FT   VARIANT     216    216       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045098.
FT   VARIANT     216    216       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045099.
FT   VARIANT     216    216       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045100.
FT   VARIANT     216    216       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005956.
FT   VARIANT     216    216       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045811.
FT   VARIANT     217    217       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045101.
FT   VARIANT     217    217       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045102.
FT   VARIANT     217    217       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045103.
FT   VARIANT     217    217       V -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045104.
FT   VARIANT     217    217       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045105.
FT   VARIANT     217    217       V -> M (in dbSNP:rs35163653).
FT                                /FTId=VAR_047178.
FT   VARIANT     218    218       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045106.
FT   VARIANT     218    218       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045107.
FT   VARIANT     218    218       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045108.
FT   VARIANT     218    218       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045109.
FT   VARIANT     218    218       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045110.
FT   VARIANT     219    219       P -> C (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045812.
FT   VARIANT     219    219       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045111.
FT   VARIANT     219    219       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045112.
FT   VARIANT     219    219       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045113.
FT   VARIANT     219    219       P -> S (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045114.
FT   VARIANT     219    219       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045115.
FT   VARIANT     220    220       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005957.
FT   VARIANT     220    220       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045116.
FT   VARIANT     220    220       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045117.
FT   VARIANT     220    220       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005958.
FT   VARIANT     220    220       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045118.
FT   VARIANT     220    220       Y -> S (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005959.
FT   VARIANT     221    221       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045119.
FT   VARIANT     221    221       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045120.
FT   VARIANT     221    221       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045121.
FT   VARIANT     221    221       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045122.
FT   VARIANT     221    221       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045123.
FT   VARIANT     222    222       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045124.
FT   VARIANT     222    222       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045125.
FT   VARIANT     222    222       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045126.
FT   VARIANT     222    222       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045127.
FT   VARIANT     222    222       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045128.
FT   VARIANT     222    222       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045129.
FT   VARIANT     223    223       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047179.
FT   VARIANT     223    223       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045130.
FT   VARIANT     223    223       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045131.
FT   VARIANT     223    223       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045132.
FT   VARIANT     223    223       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045133.
FT   VARIANT     223    223       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045134.
FT   VARIANT     224    224       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045135.
FT   VARIANT     224    224       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045136.
FT   VARIANT     224    224       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045137.
FT   VARIANT     224    224       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045138.
FT   VARIANT     225    225       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045139.
FT   VARIANT     225    225       V -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045140.
FT   VARIANT     225    225       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045141.
FT   VARIANT     225    225       V -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045142.
FT   VARIANT     225    225       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045143.
FT   VARIANT     225    225       V -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045144.
FT   VARIANT     226    226       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045145.
FT   VARIANT     226    226       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047180.
FT   VARIANT     226    226       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045844.
FT   VARIANT     226    226       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045146.
FT   VARIANT     226    226       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045147.
FT   VARIANT     227    227       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045148.
FT   VARIANT     227    227       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045149.
FT   VARIANT     227    227       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045150.
FT   VARIANT     227    227       S -> T (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045151.
FT   VARIANT     228    228       D -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045152.
FT   VARIANT     228    228       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005960.
FT   VARIANT     228    228       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045153.
FT   VARIANT     228    228       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045154.
FT   VARIANT     228    228       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045155.
FT   VARIANT     228    228       D -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045845.
FT   VARIANT     228    228       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045156.
FT   VARIANT     228    228       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045157.
FT   VARIANT     229    229       C -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045158.
FT   VARIANT     229    229       C -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045846.
FT   VARIANT     229    229       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045159.
FT   VARIANT     229    229       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045160.
FT   VARIANT     229    229       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045161.
FT   VARIANT     230    230       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045162.
FT   VARIANT     230    230       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005961.
FT   VARIANT     230    230       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045163.
FT   VARIANT     230    230       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045164.
FT   VARIANT     230    230       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045165.
FT   VARIANT     231    231       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045166.
FT   VARIANT     231    231       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045167.
FT   VARIANT     231    231       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045168.
FT   VARIANT     231    231       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045169.
FT   VARIANT     232    232       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045170.
FT   VARIANT     232    232       I -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045171.
FT   VARIANT     232    232       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045172.
FT   VARIANT     232    232       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045173.
FT   VARIANT     232    232       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005962.
FT   VARIANT     232    232       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045174.
FT   VARIANT     233    233       H -> D (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045175.
FT   VARIANT     233    233       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045176.
FT   VARIANT     233    233       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045177.
FT   VARIANT     233    233       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045178.
FT   VARIANT     233    233       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047181.
FT   VARIANT     233    233       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045179.
FT   VARIANT     234    234       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005963.
FT   VARIANT     234    234       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045180.
FT   VARIANT     234    234       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045181.
FT   VARIANT     234    234       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005964.
FT   VARIANT     234    234       Y -> K (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045847.
FT   VARIANT     234    234       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045182.
FT   VARIANT     234    234       Y -> Q (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045848.
FT   VARIANT     234    234       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045183.
FT   VARIANT     235    235       N -> D (in an adrenocortical carcinoma
FT                                with no family history; germline mutation
FT                                and in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047182.
FT   VARIANT     235    235       N -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045184.
FT   VARIANT     235    235       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045185.
FT   VARIANT     235    235       N -> M (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045849.
FT   VARIANT     235    235       N -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045186.
FT   VARIANT     235    235       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045187.
FT   VARIANT     235    235       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045188.
FT   VARIANT     236    236       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045189.
FT   VARIANT     236    236       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045190.
FT   VARIANT     236    236       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045191.
FT   VARIANT     236    236       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045192.
FT   VARIANT     236    236       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045193.
FT   VARIANT     236    236       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045194.
FT   VARIANT     237    237       M -> I (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005965.
FT   VARIANT     237    237       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045195.
FT   VARIANT     237    237       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045196.
FT   VARIANT     237    237       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045197.
FT   VARIANT     237    237       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045198.
FT   VARIANT     237    237       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045199.
FT   VARIANT     238    238       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005966.
FT   VARIANT     238    238       C -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045200.
FT   VARIANT     238    238       C -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045850.
FT   VARIANT     238    238       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045201.
FT   VARIANT     238    238       C -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045202.
FT   VARIANT     238    238       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045203.
FT   VARIANT     238    238       C -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_005967.
FT   VARIANT     239    239       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045204.
FT   VARIANT     239    239       N -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045205.
FT   VARIANT     239    239       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045206.
FT   VARIANT     239    239       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045207.
FT   VARIANT     239    239       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045208.
FT   VARIANT     239    239       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045209.
FT   VARIANT     239    239       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045210.
FT   VARIANT     240    240       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045211.
FT   VARIANT     240    240       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045212.
FT   VARIANT     240    240       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005968.
FT   VARIANT     240    240       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045213.
FT   VARIANT     240    240       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045214.
FT   VARIANT     240    240       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045215.
FT   VARIANT     240    240       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045216.
FT   VARIANT     241    241       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033036.
FT   VARIANT     241    241       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045217.
FT   VARIANT     241    241       S -> F (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934573).
FT                                /FTId=VAR_005969.
FT   VARIANT     241    241       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045218.
FT   VARIANT     241    241       S -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047183.
FT   VARIANT     241    241       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045219.
FT   VARIANT     242    242       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005970.
FT   VARIANT     242    242       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045220.
FT   VARIANT     242    242       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045221.
FT   VARIANT     242    242       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045222.
FT   VARIANT     242    242       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045223.
FT   VARIANT     242    242       C -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045224.
FT   VARIANT     243    244       MG -> IC (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047184.
FT   VARIANT     243    244       MG -> IS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047185.
FT   VARIANT     243    243       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045225.
FT   VARIANT     243    243       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045226.
FT   VARIANT     243    243       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045227.
FT   VARIANT     243    243       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045228.
FT   VARIANT     243    243       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045229.
FT   VARIANT     243    243       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045230.
FT   VARIANT     244    244       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047186.
FT   VARIANT     244    244       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045231.
FT   VARIANT     244    244       G -> D (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934572).
FT                                /FTId=VAR_045232.
FT   VARIANT     244    244       G -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045233.
FT   VARIANT     244    244       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045234.
FT   VARIANT     244    244       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045235.
FT   VARIANT     244    244       G -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045236.
FT   VARIANT     245    245       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005971.
FT   VARIANT     245    245       G -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005972.
FT   VARIANT     245    245       G -> D (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005973.
FT   VARIANT     245    245       G -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045237.
FT   VARIANT     245    245       G -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045851.
FT   VARIANT     245    245       G -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045852.
FT   VARIANT     245    245       G -> L (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045853.
FT   VARIANT     245    245       G -> N (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045854.
FT   VARIANT     245    245       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045238.
FT   VARIANT     245    245       G -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934575).
FT                                /FTId=VAR_005974.
FT   VARIANT     245    245       G -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005975.
FT   VARIANT     246    246       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045239.
FT   VARIANT     246    246       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045240.
FT   VARIANT     246    246       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044020.
FT   VARIANT     246    246       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005976.
FT   VARIANT     246    246       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005977.
FT   VARIANT     246    246       M -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005978.
FT   VARIANT     247    248       NR -> IP (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047187.
FT   VARIANT     247    248       NR -> KW (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047188.
FT   VARIANT     247    247       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045241.
FT   VARIANT     247    247       N -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045855.
FT   VARIANT     247    247       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005980.
FT   VARIANT     247    247       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045242.
FT   VARIANT     247    247       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045243.
FT   VARIANT     247    247       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047189.
FT   VARIANT     247    247       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045244.
FT   VARIANT     248    248       R -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045245.
FT   VARIANT     248    248       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005981.
FT   VARIANT     248    248       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005982.
FT   VARIANT     248    248       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045246.
FT   VARIANT     248    248       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs11540652).
FT                                /FTId=VAR_005983.
FT   VARIANT     248    248       R -> W (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005984.
FT   VARIANT     249    250       RP -> SA (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047190.
FT   VARIANT     249    250       RP -> SS (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047191.
FT   VARIANT     249    249       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005985.
FT   VARIANT     249    249       R -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045247.
FT   VARIANT     249    249       R -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045248.
FT   VARIANT     249    249       R -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033037.
FT   VARIANT     249    249       R -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045856.
FT   VARIANT     249    249       R -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs28934571).
FT                                /FTId=VAR_005986.
FT   VARIANT     249    249       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045249.
FT   VARIANT     249    249       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045250.
FT   VARIANT     250    250       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045251.
FT   VARIANT     250    250       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045857.
FT   VARIANT     250    250       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045252.
FT   VARIANT     250    250       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047192.
FT   VARIANT     250    250       P -> N (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045858.
FT   VARIANT     250    250       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045253.
FT   VARIANT     250    250       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045254.
FT   VARIANT     250    250       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045255.
FT   VARIANT     251    251       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045256.
FT   VARIANT     251    251       I -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045257.
FT   VARIANT     251    251       I -> M (in LFS; germline mutation).
FT                                /FTId=VAR_045258.
FT   VARIANT     251    251       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005987.
FT   VARIANT     251    251       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033038.
FT   VARIANT     251    251       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045259.
FT   VARIANT     251    251       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045260.
FT   VARIANT     252    252       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045261.
FT   VARIANT     252    252       L -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045262.
FT   VARIANT     252    252       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045263.
FT   VARIANT     252    252       L -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005988.
FT   VARIANT     252    252       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045264.
FT   VARIANT     253    253       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045265.
FT   VARIANT     253    253       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045266.
FT   VARIANT     253    253       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045267.
FT   VARIANT     253    253       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047193.
FT   VARIANT     253    253       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045268.
FT   VARIANT     254    254       I -> D (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045859.
FT   VARIANT     254    254       I -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045269.
FT   VARIANT     254    254       I -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045270.
FT   VARIANT     254    254       I -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045271.
FT   VARIANT     254    254       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_017908.
FT   VARIANT     254    254       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045272.
FT   VARIANT     254    254       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_017909.
FT   VARIANT     254    254       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045273.
FT   VARIANT     255    255       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045274.
FT   VARIANT     255    255       I -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045275.
FT   VARIANT     255    255       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045276.
FT   VARIANT     255    255       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045277.
FT   VARIANT     255    255       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045278.
FT   VARIANT     255    255       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045279.
FT   VARIANT     256    256       T -> I (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045280.
FT   VARIANT     256    256       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045281.
FT   VARIANT     256    256       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045282.
FT   VARIANT     256    256       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045283.
FT   VARIANT     257    257       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005989.
FT   VARIANT     257    257       L -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934577).
FT                                /FTId=VAR_045284.
FT   VARIANT     257    257       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045285.
FT   VARIANT     257    257       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045286.
FT   VARIANT     258    258       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045287.
FT   VARIANT     258    258       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005990.
FT   VARIANT     258    258       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045288.
FT   VARIANT     258    258       E -> K (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005991.
FT   VARIANT     258    258       E -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045860.
FT   VARIANT     258    258       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045289.
FT   VARIANT     258    258       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045290.
FT   VARIANT     259    259       D -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047194.
FT   VARIANT     259    259       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045291.
FT   VARIANT     259    259       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045292.
FT   VARIANT     259    259       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045293.
FT   VARIANT     259    259       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045294.
FT   VARIANT     259    259       D -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045861.
FT   VARIANT     259    259       D -> S (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045862.
FT   VARIANT     259    259       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045295.
FT   VARIANT     259    259       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033039.
FT   VARIANT     260    260       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045296.
FT   VARIANT     260    260       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045297.
FT   VARIANT     260    260       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045298.
FT   VARIANT     260    260       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045299.
FT   VARIANT     260    260       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045300.
FT   VARIANT     260    260       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045301.
FT   VARIANT     261    261       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045302.
FT   VARIANT     261    261       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045303.
FT   VARIANT     261    261       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045304.
FT   VARIANT     261    261       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045305.
FT   VARIANT     261    261       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045306.
FT   VARIANT     262    263       GN -> PD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047195.
FT   VARIANT     262    262       G -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045307.
FT   VARIANT     262    262       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047196.
FT   VARIANT     262    262       G -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045863.
FT   VARIANT     262    262       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045308.
FT   VARIANT     262    262       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045309.
FT   VARIANT     263    263       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045310.
FT   VARIANT     263    263       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045311.
FT   VARIANT     263    263       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045312.
FT   VARIANT     263    263       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045313.
FT   VARIANT     263    263       N -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045314.
FT   VARIANT     264    264       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045315.
FT   VARIANT     264    264       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045316.
FT   VARIANT     264    264       L -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045317.
FT   VARIANT     264    264       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045318.
FT   VARIANT     264    264       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045319.
FT   VARIANT     265    265       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045320.
FT   VARIANT     265    265       L -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045321.
FT   VARIANT     265    265       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045322.
FT   VARIANT     265    265       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047197.
FT   VARIANT     266    266       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045323.
FT   VARIANT     266    266       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045324.
FT   VARIANT     266    266       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045325.
FT   VARIANT     266    266       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045326.
FT   VARIANT     267    267       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045327.
FT   VARIANT     267    267       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045328.
FT   VARIANT     267    267       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045329.
FT   VARIANT     267    267       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045330.
FT   VARIANT     267    267       R -> W (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs55832599).
FT                                /FTId=VAR_036507.
FT   VARIANT     268    268       N -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045864.
FT   VARIANT     268    268       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045331.
FT   VARIANT     268    268       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045332.
FT   VARIANT     268    268       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045333.
FT   VARIANT     268    268       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045334.
FT   VARIANT     268    268       N -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045335.
FT   VARIANT     269    269       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045336.
FT   VARIANT     269    269       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045337.
FT   VARIANT     269    269       S -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047198.
FT   VARIANT     269    269       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045338.
FT   VARIANT     269    269       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045339.
FT   VARIANT     269    269       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045340.
FT   VARIANT     270    270       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045341.
FT   VARIANT     270    270       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045342.
FT   VARIANT     270    270       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045343.
FT   VARIANT     270    270       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045344.
FT   VARIANT     270    270       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045345.
FT   VARIANT     270    270       F -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045346.
FT   VARIANT     271    271       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045347.
FT   VARIANT     271    271       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045348.
FT   VARIANT     271    271       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045349.
FT   VARIANT     271    271       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_036508.
FT   VARIANT     271    271       E -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045865.
FT   VARIANT     271    271       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045350.
FT   VARIANT     271    271       E -> R (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045866.
FT   VARIANT     271    271       E -> V (in an osteosarcoma with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047199.
FT   VARIANT     272    272       V -> A (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045351.
FT   VARIANT     272    272       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045352.
FT   VARIANT     272    272       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045353.
FT   VARIANT     272    272       V -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005992.
FT   VARIANT     272    272       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045354.
FT   VARIANT     273    273       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005993.
FT   VARIANT     273    273       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005994.
FT   VARIANT     273    273       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                abolishes sequence-specific DNA binding;
FT                                dbSNP:rs28934576).
FT                                /FTId=VAR_005995.
FT   VARIANT     273    273       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_036509.
FT   VARIANT     273    273       R -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045867.
FT   VARIANT     273    273       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045355.
FT   VARIANT     273    273       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045356.
FT   VARIANT     273    273       R -> S (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045357.
FT   VARIANT     273    273       R -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045868.
FT   VARIANT     274    274       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045358.
FT   VARIANT     274    274       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045359.
FT   VARIANT     274    274       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005997.
FT   VARIANT     274    274       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047200.
FT   VARIANT     274    274       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045360.
FT   VARIANT     274    274       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045361.
FT   VARIANT     275    275       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045362.
FT   VARIANT     275    275       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045363.
FT   VARIANT     275    275       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045364.
FT   VARIANT     275    275       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045365.
FT   VARIANT     275    275       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005999.
FT   VARIANT     275    275       C -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005998.
FT   VARIANT     276    276       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045366.
FT   VARIANT     276    276       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045367.
FT   VARIANT     276    276       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045368.
FT   VARIANT     276    276       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045369.
FT   VARIANT     276    276       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045370.
FT   VARIANT     276    276       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045371.
FT   VARIANT     277    277       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045372.
FT   VARIANT     277    277       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006000.
FT   VARIANT     277    277       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045373.
FT   VARIANT     277    277       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045374.
FT   VARIANT     277    277       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047201.
FT   VARIANT     277    277       C -> Y (in an osteosarcoma with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045375.
FT   VARIANT     278    278       P -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs17849781).
FT                                /FTId=VAR_006001.
FT   VARIANT     278    278       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045869.
FT   VARIANT     278    278       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006002.
FT   VARIANT     278    278       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006003.
FT   VARIANT     278    278       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045376.
FT   VARIANT     278    278       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006004.
FT   VARIANT     278    278       P -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006005.
FT   VARIANT     279    279       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006006.
FT   VARIANT     279    279       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045377.
FT   VARIANT     279    279       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045378.
FT   VARIANT     279    279       G -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045379.
FT   VARIANT     280    280       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045380.
FT   VARIANT     280    280       R -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006008.
FT   VARIANT     280    280       R -> K (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_006007.
FT   VARIANT     280    280       R -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045381.
FT   VARIANT     280    280       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045382.
FT   VARIANT     280    280       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006009.
FT   VARIANT     281    282       DR -> EW (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047203.
FT   VARIANT     281    281       D -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006010.
FT   VARIANT     281    281       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006011.
FT   VARIANT     281    281       D -> G (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006012.
FT   VARIANT     281    281       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006013.
FT   VARIANT     281    281       D -> N (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047202.
FT   VARIANT     281    281       D -> R (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045870.
FT   VARIANT     281    281       D -> V (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_006014.
FT   VARIANT     281    281       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045383.
FT   VARIANT     282    282       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045384.
FT   VARIANT     282    282       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045385.
FT   VARIANT     282    282       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006015.
FT   VARIANT     282    282       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045386.
FT   VARIANT     282    282       R -> Q (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045387.
FT   VARIANT     282    282       R -> W (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934574).
FT                                /FTId=VAR_006016.
FT   VARIANT     283    283       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006017.
FT   VARIANT     283    283       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006018.
FT   VARIANT     283    283       R -> H (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006019.
FT   VARIANT     283    283       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045388.
FT   VARIANT     283    283       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006020.
FT   VARIANT     283    283       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045389.
FT   VARIANT     284    284       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006021.
FT   VARIANT     284    284       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045390.
FT   VARIANT     284    284       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045391.
FT   VARIANT     284    284       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006022.
FT   VARIANT     285    285       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045392.
FT   VARIANT     285    285       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045393.
FT   VARIANT     285    285       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045394.
FT   VARIANT     285    285       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006023.
FT   VARIANT     285    285       E -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006024.
FT   VARIANT     285    285       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006025.
FT   VARIANT     286    286       E -> A (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006026.
FT   VARIANT     286    286       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006027.
FT   VARIANT     286    286       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006028.
FT   VARIANT     286    286       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006029.
FT   VARIANT     286    286       E -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045871.
FT   VARIANT     286    286       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006030.
FT   VARIANT     286    286       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045395.
FT   VARIANT     287    287       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047204.
FT   VARIANT     287    287       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045396.
FT   VARIANT     287    287       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045397.
FT   VARIANT     287    287       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045398.
FT   VARIANT     287    287       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045399.
FT   VARIANT     288    288       N -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045400.
FT   VARIANT     288    288       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045401.
FT   VARIANT     288    288       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045402.
FT   VARIANT     288    288       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045403.
FT   VARIANT     288    288       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045404.
FT   VARIANT     289    289       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045405.
FT   VARIANT     289    289       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045406.
FT   VARIANT     289    289       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045407.
FT   VARIANT     289    289       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045408.
FT   VARIANT     289    289       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045409.
FT   VARIANT     290    290       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045410.
FT   VARIANT     290    290       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs55819519).
FT                                /FTId=VAR_045411.
FT   VARIANT     290    290       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045412.
FT   VARIANT     291    291       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045413.
FT   VARIANT     291    291       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045414.
FT   VARIANT     291    291       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045415.
FT   VARIANT     291    291       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047205.
FT   VARIANT     291    291       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045416.
FT   VARIANT     291    291       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045417.
FT   VARIANT     292    292       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045418.
FT   VARIANT     292    292       K -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045872.
FT   VARIANT     292    292       K -> I (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_015819.
FT   VARIANT     292    292       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045419.
FT   VARIANT     292    292       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045420.
FT   VARIANT     292    292       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045421.
FT   VARIANT     292    292       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045422.
FT   VARIANT     293    293       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045423.
FT   VARIANT     293    293       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045424.
FT   VARIANT     293    293       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045425.
FT   VARIANT     293    293       G -> W (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045426.
FT   VARIANT     294    294       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045427.
FT   VARIANT     294    294       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045428.
FT   VARIANT     294    294       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045429.
FT   VARIANT     294    294       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047206.
FT   VARIANT     294    294       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045430.
FT   VARIANT     294    294       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045431.
FT   VARIANT     295    295       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045432.
FT   VARIANT     295    295       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045433.
FT   VARIANT     295    295       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045434.
FT   VARIANT     295    295       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045435.
FT   VARIANT     296    296       H -> C (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045873.
FT   VARIANT     296    296       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045436.
FT   VARIANT     296    296       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047207.
FT   VARIANT     296    296       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045437.
FT   VARIANT     296    296       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006031.
FT   VARIANT     296    296       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045438.
FT   VARIANT     296    296       H -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045439.
FT   VARIANT     296    296       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045440.
FT   VARIANT     297    297       H -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045441.
FT   VARIANT     297    297       H -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045442.
FT   VARIANT     297    297       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045443.
FT   VARIANT     297    297       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045444.
FT   VARIANT     297    297       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045445.
FT   VARIANT     298    298       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045446.
FT   VARIANT     298    298       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045447.
FT   VARIANT     298    298       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045448.
FT   VARIANT     298    298       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045449.
FT   VARIANT     298    298       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045450.
FT   VARIANT     299    299       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045451.
FT   VARIANT     299    299       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045452.
FT   VARIANT     299    299       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045453.
FT   VARIANT     299    299       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045454.
FT   VARIANT     300    300       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045455.
FT   VARIANT     300    300       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045456.
FT   VARIANT     300    300       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006032.
FT   VARIANT     300    300       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045457.
FT   VARIANT     301    301       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045458.
FT   VARIANT     301    301       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006033.
FT   VARIANT     301    301       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045459.
FT   VARIANT     301    301       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045460.
FT   VARIANT     301    301       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047208.
FT   VARIANT     302    302       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045461.
FT   VARIANT     302    302       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006034.
FT   VARIANT     302    302       G -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045462.
FT   VARIANT     302    302       G -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006035.
FT   VARIANT     303    303       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045463.
FT   VARIANT     303    303       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045464.
FT   VARIANT     303    303       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045465.
FT   VARIANT     303    303       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045466.
FT   VARIANT     304    304       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045467.
FT   VARIANT     304    304       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045468.
FT   VARIANT     304    304       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045469.
FT   VARIANT     304    304       T -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047209.
FT   VARIANT     305    305       K -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045470.
FT   VARIANT     305    305       K -> M (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045471.
FT   VARIANT     305    305       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045472.
FT   VARIANT     305    305       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045473.
FT   VARIANT     305    305       K -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045474.
FT   VARIANT     306    306       R -> P (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045475.
FT   VARIANT     306    306       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006036.
FT   VARIANT     307    307       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045476.
FT   VARIANT     307    307       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045477.
FT   VARIANT     307    307       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006037.
FT   VARIANT     308    308       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045478.
FT   VARIANT     308    308       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045479.
FT   VARIANT     309    309       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045480.
FT   VARIANT     309    309       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006038.
FT   VARIANT     310    310       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045481.
FT   VARIANT     310    310       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045482.
FT   VARIANT     311    311       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045483.
FT   VARIANT     311    311       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045484.
FT   VARIANT     311    311       N -> S (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs56184981).
FT                                /FTId=VAR_045485.
FT   VARIANT     311    311       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045486.
FT   VARIANT     312    312       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045487.
FT   VARIANT     312    312       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045488.
FT   VARIANT     313    313       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045489.
FT   VARIANT     313    313       S -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045490.
FT   VARIANT     313    313       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045491.
FT   VARIANT     313    313       S -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045492.
FT   VARIANT     314    314       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045493.
FT   VARIANT     315    315       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045494.
FT   VARIANT     315    315       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045495.
FT   VARIANT     315    315       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045496.
FT   VARIANT     316    316       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045497.
FT   VARIANT     316    316       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045498.
FT   VARIANT     317    317       Q -> H (in a kidney cancer with no family
FT                                history; germline mutation and in a
FT                                sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045499.
FT   VARIANT     317    317       Q -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045500.
FT   VARIANT     317    317       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047210.
FT   VARIANT     317    317       Q -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045501.
FT   VARIANT     317    317       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045502.
FT   VARIANT     318    318       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045503.
FT   VARIANT     319    319       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045504.
FT   VARIANT     319    319       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045505.
FT   VARIANT     319    319       K -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045506.
FT   VARIANT     320    320       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045507.
FT   VARIANT     321    321       K -> E (in kidney cancer; germline
FT                                mutation).
FT                                /FTId=VAR_045508.
FT   VARIANT     321    321       K -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045509.
FT   VARIANT     322    322       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045510.
FT   VARIANT     322    322       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045511.
FT   VARIANT     323    323       L -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045874.
FT   VARIANT     323    323       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045512.
FT   VARIANT     323    323       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045513.
FT   VARIANT     323    323       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045514.
FT   VARIANT     323    323       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047211.
FT   VARIANT     324    324       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045515.
FT   VARIANT     324    324       D -> S (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045875.
FT   VARIANT     324    324       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045516.
FT   VARIANT     325    325       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045517.
FT   VARIANT     325    325       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045518.
FT   VARIANT     325    325       G -> V (in LFS; germline mutation;
FT                                dbSNP:rs28934271).
FT                                /FTId=VAR_006039.
FT   VARIANT     326    326       E -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045519.
FT   VARIANT     327    327       Y -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045520.
FT   VARIANT     327    327       Y -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045521.
FT   VARIANT     328    328       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045522.
FT   VARIANT     328    328       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045523.
FT   VARIANT     328    328       F -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045524.
FT   VARIANT     329    329       T -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045525.
FT   VARIANT     329    329       T -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045526.
FT   VARIANT     330    330       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045527.
FT   VARIANT     330    330       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047212.
FT   VARIANT     330    330       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045528.
FT   VARIANT     331    331       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045529.
FT   VARIANT     331    331       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045530.
FT   VARIANT     331    331       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045531.
FT   VARIANT     332    332       I -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045532.
FT   VARIANT     334    334       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006040.
FT   VARIANT     334    334       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045533.
FT   VARIANT     335    335       R -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045534.
FT   VARIANT     335    335       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045535.
FT   VARIANT     335    335       R -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045536.
FT   VARIANT     337    337       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006041.
FT   VARIANT     337    337       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_035016.
FT   VARIANT     337    337       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045537.
FT   VARIANT     337    337       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045538.
FT   VARIANT     338    338       F -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045539.
FT   VARIANT     338    338       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045540.
FT   VARIANT     339    339       E -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs17882252).
FT                                /FTId=VAR_022316.
FT   VARIANT     339    339       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045541.
FT   VARIANT     341    341       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045542.
FT   VARIANT     342    342       R -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045543.
FT   VARIANT     342    342       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045544.
FT   VARIANT     342    342       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047213.
FT   VARIANT     343    343       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045545.
FT   VARIANT     344    344       L -> P (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045546.
FT   VARIANT     344    344       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045547.
FT   VARIANT     346    346       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045548.
FT   VARIANT     347    347       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045549.
FT   VARIANT     347    347       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045550.
FT   VARIANT     348    348       L -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045551.
FT   VARIANT     348    348       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045552.
FT   VARIANT     349    349       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045553.
FT   VARIANT     352    352       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045554.
FT   VARIANT     353    353       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045555.
FT   VARIANT     354    354       Q -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045556.
FT   VARIANT     354    354       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045557.
FT   VARIANT     354    354       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047214.
FT   VARIANT     356    356       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045558.
FT   VARIANT     356    356       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045559.
FT   VARIANT     358    358       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045560.
FT   VARIANT     358    358       E -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045561.
FT   VARIANT     360    360       G -> A (in dbSNP:rs35993958).
FT                                /FTId=VAR_045562.
FT   VARIANT     360    360       G -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045563.
FT   VARIANT     363    363       R -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045564.
FT   VARIANT     364    364       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045565.
FT   VARIANT     364    364       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045566.
FT   VARIANT     364    364       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045567.
FT   VARIANT     365    365       H -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047215.
FT   VARIANT     365    365       H -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in a sporadic
FT                                cancer; somatic mutation).
FT                                /FTId=VAR_045568.
FT   VARIANT     366    366       S -> A (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs17881470).
FT                                /FTId=VAR_022317.
FT   VARIANT     370    370       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045569.
FT   VARIANT     376    376       S -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045570.
FT   VARIANT     376    376       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045571.
FT   VARIANT     379    379       R -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045572.
FT   VARIANT     385    385       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045573.
FT   VARIANT     389    389       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045574.
FT   VARIANT     392    392       S -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045575.
FT   MUTAGEN      15     15       S->A: Loss of interaction with PPP2R5C,
FT                                PPP2CA AND PPP2R1A.
FT   MUTAGEN      18     18       T->A: No effect on interaction with MDM2
FT                                and increase in protein levels after DNA
FT                                damage.
FT   MUTAGEN      20     20       S->A: Abolishes phosphorylation site.
FT                                Abolishes increase in protein levels
FT                                after DNA damage.
FT   MUTAGEN      20     20       S->D: Constitutively increased TP53
FT                                protein levels.
FT   MUTAGEN      22     23       LW->QS: Loss of interaction with MDM2,
FT                                leading to constitutively increased TP53
FT                                protein levels.
FT   MUTAGEN      46     46       S->A: Abolishes phosphorylation by HIPK2
FT                                and acetylation of K-382 by CREBBP.
FT   MUTAGEN      46     46       Missing: Alters interaction with WWOX.
FT   MUTAGEN      55     55       T->A: Blocks phosphorylation by TAF1.
FT   MUTAGEN     291    292       KK->RR: Abolishes polyubiquitination by
FT                                MKRN1.
FT   MUTAGEN     359    359       P->D: Abolishes binding to USP7.
FT   MUTAGEN     361    361       G->E: Abolishes binding to USP7.
FT   MUTAGEN     362    362       S->A: Abolishes binding to USP7.
FT   MUTAGEN     370    370       K->R: Induces a decrease in methylation
FT                                by SMYD2.
FT   MUTAGEN     372    372       K->R: Induces a decrease in protein
FT                                stabilization.
FT   MUTAGEN     373    373       K->R: Abolishes dimethylation by EHMT1
FT                                and EHMT2.
FT   MUTAGEN     382    382       K->A: Abolishes acetylation by CREBBP.
FT   MUTAGEN     382    382       K->R: Abolishes monomethylation by SETD8.
FT   MUTAGEN     385    385       F->A: Reduced SUMO1 conjugation.
FT   MUTAGEN     386    386       K->A: Abolishes SUMO1 conjugation, in
FT                                vitro and in vivo.
FT   MUTAGEN     387    387       T->A: No effect SUMO1 conjugation.
FT   MUTAGEN     388    388       E->A: Abolishes SUMO1 conjugation.
FT   HELIX        19     23
FT   HELIX        36     38
FT   HELIX        41     44
FT   HELIX        47     55
FT   TURN        105    108
FT   STRAND      110    112
FT   STRAND      123    127
FT   TURN        128    131
FT   STRAND      132    135
FT   STRAND      141    146
FT   STRAND      156    165
FT   HELIX       166    168
FT   HELIX       177    180
FT   STRAND      187    189
FT   STRAND      194    199
FT   STRAND      204    207
FT   TURN        209    211
FT   STRAND      214    219
FT   STRAND      228    236
FT   TURN        243    248
FT   STRAND      251    258
FT   STRAND      264    274
FT   HELIX       278    287
FT   STRAND      327    334
FT   HELIX       335    354
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
